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ABSTRACT

The Human Papillomavirus (HPV) is an extremely prevalent and sexually
transmitted infection that is a known cause of morbidities such as genital warts and
cancers of the cervix, anus, and oropharynx. Non-cervical HPV-related cancers have been
a developing problem in North America, increasing in incidence by up to 225% in some
instances over a span of two decades.
This study investigated levels of awareness and knowledge of HPV,
Oropharyngeal Cancer (OPC), and the HPV vaccine using a self-administered web-based
survey designed specifically for this research. University students (n=1,005) aged 18-30
completed a 42-item questionnaire that included demographic information, awareness
questions, and a series of “true/false/I don’t know” knowledge questions. Results
revealed that participants had relatively high levels of awareness. However, many
respondents had significant gaps in their knowledge of HPV, OPC, and the HPV vaccine.
These data suggest that further efforts to educate young adults on these topics are
warranted.
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CHAPTER 1
Introduction and Review of Literature
Overview. The Human Papillomavirus (HPV) has been described as an ‘equal
opportunity’ pathogen as much a part of the human condition as sexuality itself (Bosch et
al., 2013). Up to 80% of sexually active people will acquire an HPV infection of some
type at one time in their life (Bosch et al., 2013), making HPV the most common sexually
transmitted infection in the world. At present, there are more than 120 identified strains
of HPV, over 40 of which infect the anogenital tract (Munoz, Castellsagué, & de
Gonzalez, 2006).
The role of HPV as a human carcinogen was solidified in the late 1970’s, when
Dr. Harold zur Hausen discovered the causal link between HPV infections and cervical
cancer (Nour, 2009). To this day, cervical cancer remains a significant global health
burden, affecting over 500,000 women each year worldwide (Torre et al., 2015). HPV
infection remains essentially the sole cause of this cancer (Walboomers et al., 1999). As
such, most fields of HPV research (epidemiology, prevention, interventions, etc.) have
traditionally been studied from the perspective of cervical cancer in females. While this
work has been vital to understanding the virus, HPV research has expanded in recent
decades, as the causative role of HPV in other non-cervical cancers and morbidities has
been uncovered.
The vast majority of HPV infections occur without perceptible symptoms and
approximately 91% of infections clear spontaneously within two years, with the mean
duration of infection being 8 months (Ho, Bierman, Beardsley, Change, & Burk, 1998).
When symptoms do arise, they may manifest as anogenital warts (most commonly due to
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infection with either HPV strain 6 or 11) or as precancerous lesions of the anogenital tract
(most commonly due to infection with “high risk” strains 16 or 18) (Bosch et al., 2013).
Although unpleasant, anogenital warts are typically benign and pose no serious health
risks. Therefore, infection with HPV strains 6 or 11 is considered “low risk”. On the
contrary, HPV strains 16, 18 (and to a lesser extent HPV strains 31, 33, 45, 52, 58 and
others) are considered “high risk” because they are found in the majority of HPV-related
cancers (Bosch et al., 2013). These HPV-related cancers typically begin as precancerous
lesions that may remain dormant or grow undetected for decades. In economically and
socially developed countries, cervical screening programs for women have been effective
in detecting and treating these precancerous lesions before they transform into cancer.
However, very few screening programs exist for women in developing areas of the world.
Furthermore, HPV screening interventions are limited to the cervix only; therefore, such
programs do not include the screening of men or for other anatomical areas of potential
infection in either gender.
HPV is transmitted through skin-to-skin contact with the anogenital region. This
may include any form of intimate sexual contact such as oral, vaginal, or anal sex.
Evidence also suggests that HPV can be transmitted orally through open mouth kissing
(Gillison et al., 2012; Pickard, Xiao, Broutian, He, & Gillison, 2012). However, the
typical lack of symptoms associated with HPV infection, and the ease of transmission
(i.e., skin-to-skin contact) are thought to be contributing factors to the high worldwide
prevalence of HPV infection. In the sections to follow, several issues related to HPV will
be addressed. This includes the global burden of HPV infection, HPV-related morbidities
and mortality, HPV vaccination efforts, and public awareness and knowledge of HPV.
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Global Burden of HPV Infection
As mentioned previously, HPV is the most common sexually transmitted
infection in the world. In a meta-analysis of 194 studies assessing HPV prevalence in
over 1 million females, the global prevalence of cervical HPV infection was found to be
11.7% (Bruni et al., 2010). Prevalence rates have been shown to range from up to 35% in
developing regions such as eastern Africa and central America to below 10% in more
developed regions of North America and Europe (Bruni et al., 2010). Across all
geographic regions, both developed and non-developed, prevalence of cervical HPV
infection was highest among females under the age of 25. In this age group, prevalence
was 24% globally (Bruni et al., 2010). Many North American studies also have noted that
the peak prevalence of cervical HPV infection occurs in university/college aged females
(age 20-24) and steadily declines after age 25 (Ho et al., 1998; Sellors et al., 2000;
Steinau et al., 2014; Trottier & Franco, 2006).
Although the majority of HPV strains are benign, meaning that they are rarely
associated with any substantial symptoms or morbidity, infection with certain “high risk”
strains of HPV is a known cause of certain morbidities including genital warts and
cancers of the cervix, oropharynx (including base of tongue, tonsils, soft palate, and
pharynx), anus, vulva, and penis. Approximately 96% of all cervical cancers (Muñoz et
al., 2004), 35-72% of oropharyngeal cancers (Chaturvedi et al., 2011; Kreimer, Clifford,
Boyle, & Franceschi, 2005), 78% of vaginal cancers (Daling et al., 2002), 40% of vulvar
cancers (De Vuyst, Clifford, Nascimento, Madeleine, & Franceschi, 2009), 84% of anal
cancers (De Vuyst et al., 2009), and 48% of penile cancers have been reported to contain
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HPV DNA (Backes, Kurman, Pimenta, & Smith, 2009). Thus, HPV infection represents a
significant causal factor in the development of anogenital and oropharyngeal cancers.
In particular, HPV strains 16 and 18 are responsible for the vast majority of HPVpositive tumors. More specifically, it has been reported that 70% of cervical cancers, 90%
of HPV-positive oropharyngeal cancers (Kreimer et al., 2005), and 80% of HPV-positive
anal cancers (De Vuyst et al., 2009) can be attributed to one of these two strains of the
virus. Unfortunately, these high-risk strains of HPV are also the most prevalent strains.
HPV 16 alone accounts for 22.5% of all HPV infections worldwide (Bruni et al., 2010).
Furthermore, HPV-6 and HPV-11 are known to cause over 85% of genital warts (Garland
et al., 2009).
More recently, epidemiological studies on HPV have expanded to include
consideration of men, this being a result of the rising incidence of non-cervical HPVassociated cancers (Giuliano, Lee, Fulp, Villa, Lazcano, et al., 2011; Kreimer et al., 2011;
Pickard et al., 2012). In a large multinational study of men aged 18-70, the prevalence of
genital HPV infection was found to be 50% (Giuliano, Lee, Fulp, Villa, Lazcano, et al.,
2011). Furthermore, in a large cross-sectional study of both men and women aged 14-19
in the United States, the prevalence of oral HPV infection was found to be 6.9% (Gillison
et al., 2012). Oral HPV prevalence was much higher in men compared to women (10.1%
vs. 3.6%) and, in contrast with cervical HPV infection, was more common in older
individuals (Gillison et al., 2012). Oral HPV infection was found to be eight times higher
in individuals who have had sex versus those who have not. Likewise, oral HPV infection
is also strongly associated with lifetime and recent numbers of vaginal or oral sex
partners, confirming the sexually transmitted nature of oral HPV infection (Gillison et al.,
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2012). The commonplace nature of these sexual practices in many countries, combined
with the lack of symptoms associated with HPV infection, along with other factors, likely
explains the high prevalence of infection across many geographic regions.
HPV Prevalence
Despite being a highly developed continent, North America still represents a
relatively high prevalence of HPV infections. In the United States, it has been estimated
that approximately 79 million people are currently infected with HPV (Centers for
Disease Control and Prevention, 2014). Furthermore, roughly 14 million Americans
become newly infected each year (Centers for Disease Control and Prevention, 2014). A
proportionally similar number of infections has been estimated to occur each year in
Canada; the Society of Obstetricians and Gynaecologists of Canada (2007) estimate that
between 13-26% of the adult population currently has an active HPV infection.
Fortunately, a large proportion of these infections occur from “low risk” strains of the
virus and the vast majority of all infections are transient, meaning they are self-limiting
and clear on their own. However, among the most common strains of HPV is HPV 6,
which is known to cause genital warts in some individuals. Furthermore, HPV 16, a “high
risk” strain found in the majority of HPV-related malignancies, is the second most
prevalent strain of HPV, accounting for approximately 7% of all infections (Ho et al.,
1998).
Although the majority of HPV infections are transient, persistent infection –
especially with high-risk HPV strains (i.e., HPV 16 and 18) can lead to a variety of health
conditions. While cervical cancer still represents a significant public health burden both
at home and abroad, other HPV-related cancers appear to be growing in both incidence
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and prevalence (Chaturvedi et al., 2011; Jemal et al., 2013). This trend is especially
apparent in men, who have traditionally not been thought of as being vulnerable to HPVrelated cancers. Although more attention has been paid to non-cervical HPV-related
cancers in both the scientific literature as well as the popular press in recent years,
cervical cancer in women still dominates the public’s relational understanding of HPV
and cancer. This more focused attention and understanding exists despite a relatively
equal burden of HPV-related cancer between both genders when other anatomical sites
(such as the oropharynx and anus) are considered. Increasing public awareness of these
non-cervical cancers, especially in men, may pose a valuable opportunity for prevention.
However, increasing attention on non-cervical HPV cancers should not come at the
expense of cervical cancer awareness.
HPV-Related Morbidities and Mortalities
As mentioned previously, HPV represents a major source of morbidity and
mortality worldwide. Although great strides have been made in understanding this virus,
infection rates remain high, especially in those under the age of 25 (Bruni et al., 2010;
Steinau et al., 2014). Unfortunately, HPV strains that are known causes of morbidity are
also the most prevalent. Most notably, HPV 16 and 18, which are found in the
overwhelming majority of HPV-related cancers, are the two most prevalent strains,
respectively (Bruni et al., 2010). Furthermore, HPV 6, which causes genital warts in
some individuals, is the fourth most prevalent strain in North America (Bruni et al.,
2010). These morbidities will be discussed further in the following paragraphs.
Genital Warts. Anogenital warts are by far the most common consequence of
HPV infection. As mentioned previously, HPV strains 6 and 11 account for over 85% of
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all cases of genital warts (Garland et al., 2009). Genital warts manifest as benign, but
visible lesions around one or more areas of the anogenital tract. Although benign, genital
warts may have significant psychological and social consequences for the infected
individual (Woodhall et al., 2008). They also represent a significant burden on the health
care system, as they typically recur and require ongoing management (Hoy, Singhal,
Willey, & Insinga, 2009; Lacey, Lowndes, & Shah, 2006).
Between the years 1999-2004, 5.6% of adults aged 18-59 in the United States
reported that they had been diagnosed with genital warts at one time (Dinh, Sternberg,
Dunne, & Markowitz, 2008). In both the United States and Europe, the incidence of
genital warts is highest among people aged 20-24 (Koutsky, Galloway, & Holmes, 1998).
Since the introduction of the HPV vaccine in 2007 (Mariani, Vici, Suligoi, CheccucciLisi, & Drury, 2015), studies have shown that the incidence of genital warts has
decreased substantially in countries and populations with high vaccination rates.
Australia, for example, has seen a 92.6% reduction in the incidence of genital warts in
females under 21 since the introduction of the HPV vaccination program (Mariani et al.,
2015).
HPV-Related Cancers. Of the 12.7 million new cancer diagnoses worldwide in
2008, approximately 5% can be attributed to HPV infection (De Martel et al., 2012).
Contracting HPV clearly represents a very significant burden to both the individual who
has the infection, as well as that of the health systems where one’s care may be provided.
One possible benefit to the high number of HPV-related cancers is that HPV-positive
tumors are associated with better three and/or five-year survival outcomes compared to
HPV-negative tumors of the same anatomical site; this tendency remains true for all of
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the previously discussed anatomical sites including the penis (Djajadiningrat et al., 2015),
oropharynx (Ang et al., 2010), anus (Ravenda et al., 2015), vulva and vagina (Rodrigues
et al., 2013; Sinno et al., 2014). The vastly different survival outcomes between
individuals with HPV-positive and HPV-negative tumors have led many experts to
suggest that these may be two distinctly different types of cancer. HPV-positive
oropharyngeal cancer, for example, is vastly different from HPV-negative oropharyngeal
cancer in terms of risk factors, etiology, treatment considerations, and survival outcomes
(Benson, Li, Eisele, & Fakhry, 2013; Gillison, D’Souza, et al., 2008). Similar distinctions
between HPV-positive and HPV-negative cancers have been observed at other
anatomical sites.
For example, a study by Gillison et. al (2008) found that individuals with HPVpositive head and neck cancers were more likely to be younger, college educated, have an
income greater than $50,000 per year, and be more sexually active compared to
individuals with HPV-negative head and neck cancers. Furthermore, several measures of
sexual behaviour were strongly associated with HPV-positive tumors including a higher
number of lifetime sexual partners and infrequent condom use (Gillison, D’Souza, et al.,
2008). Equally important was the fact that traditional risk factors for head and neck
cancer, that is, tobacco and heavy alcohol use, had no association with HPV-positive
tumors; however, these factors were strongly associated with HPV-negative tumors.
Analogous differences relating to associations with sexual behaviour and age of tumor
detection have also been observed between HPV-positive and HPV-negative tumours of
the penis, anus, vulva and vagina (Gillison, Chaturvedi, & Lowy, 2008).
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Cervical Cancer. Between 90-100% of cervical cancers contain HPV DNA
(Bosch, Lorincz, Muñoz, Meijer, & Shah, 2002), making the association between HPV
and cervical cancer stronger than the association between smoking and lung cancer.
Worldwide, cervical cancer is the second most common cancer diagnosed in women.
There were an estimated 527,600 new cases of cervical cancer reported in 2012
worldwide, resulting in 265,700 deaths (Torre et al., 2015). About 90% of these
mortalities occurred in developing parts of the world, where the incidence of cervical
cancer is much higher. Age-standardized incidence rates can range from as high as 42.7
per 100,000 people in Eastern Africa to 6.6 per 100,000 in developed regions such as
North America (Torre et al., 2015). The likely cause of this large geographic variation in
the rate of cervical cancer is related to the concomitant variation in genital HPV infection
rates. As with cervical cancer, genital HPV infection rates are much higher in developing
regions compared to economically and socially developed regions (Bruni et al., 2010).
In the United States, cervical cancer rates have been declining in recent decades
due to improved screening measures and the development of an HPV vaccine. HPV
screening (commonly referred to as a “Pap test”) detects infection with “high risk” strains
of HPV as well as precancerous lesions of the cervix. When test abnormalities occur,
women can be monitored or treated in an effort to prevent or reduce the likelihood of
cervical cancer developing. However, cervical cancer still affects over 12,000 women per
year, 4000 of whom succumb to the disease (Siegel, Ma, Zou, & Jemal, 2014). A
proportionately similar number of women are affected each year in Canada, with an
expected 1,450 new cases expected in 2014 (Canadian Cancer Society’s Advisory
Committee on Cancer Statistics, 2014).
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Anal Cancer. In 2002, there were 30,400 reported cases of anal cancer worldwide
(Parkin & Bray, 2006). Although a relatively uncommon cancer, the incidence of anal
cancer seems to be rising in the United States (Jemal et al., 2013). Between the years
2000 and 2009, the incidence of anal cancer increased at an average rate of 2.8% per year
in the United States (Jemal et al., 2013). Furthermore, between 84-90% of anal cancers
can be attributed to HPV (De Vuyst et al., 2009; Parkin & Bray, 2006). Due to the
sexually transmitted nature of HPV, risk of anal cancer risk is elevated for females who
engage in anal sex and homosexual males (Parkin & Bray, 2006).
Penile Cancer. There were 26,300 cases of penile cancer recorded in 2002
worldwide (Parkin & Bray, 2006). Approximately 48% of penile cancers are attributable
to HPV (Backes et al., 2009). Similar to cervical cancer, prevalence of penile cancer is
much higher in developing countries compared to parts of North America and Europe
(Backes et al., 2009). This is likely due to the higher prevalence of genital HPV infection
in these regions.
Vaginal and Vulvar Cancer. Together, these two anatomical sites accounted for
40,000 new cases of cancer worldwide in 2002 (Parkin & Bray, 2006). Approximately
70% of vaginal cancers and 40% of vulvar cancers can be attributed to HPV (De Vuyst et
al., 2009). Similar to other HPV-related cancers, the incidence of vulvar cancer also has
increased drastically in recent decades. Between the years 1973 and 2000, the incidence
of invasive vulvar cancer increased by 20% and the incidence of in situ vulvar carcinoma
increased by an astounding 411% (Judson, Habermann, Baxter, Durham, & Virnig,
2006). The discrepancy in incidence increase between these two types of vulvar cancer
has been attributed to HPV. In situ vulvar carcinoma is strongly related to HPV, whereas
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the association between invasive vulvar carcinoma is less well documented (Madeleine et
al., 1997).
Oropharyngeal Cancers. The oropharynx is complex anatomical region that is
comprised of the soft palate, posterior one third of the tongue, the tonsils, and the
circumferential structures of the throat. Over the last three decades, the incidence of
HPV-positive oropharyngeal cancer has increased by 225% in the United States
(Chaturvedi et al., 2011). Furthermore, the proportion of OPCs that were identified as
HPV-positive rose from 16.3% in 1984 to 72.7% between 2000-2004 (Chaturvedi et al.,
2011). Similar trends have been observed in Canada (Auluck et al., 2010; Nichols et al.,
2013) and other developed countries. This alarming trend has prompted organizations
such as the Center for Disease Control and Prevention (CDC), World Health
Organization, and the Canadian Cancer Society to label the rising incidence of
oropharyngeal cancer as an epidemic.
Meanwhile, the incidence of HPV-negative OPC decreased by 50% between 1988
and 2004 in the United States (Chaturvedi et al., 2011). Furthermore, oral cavity cancers
and lung cancer, which have traditionally shared the same risk factors as OPC (i.e., heavy
smoking and alcohol use), significantly decreased during the same time period in
developed countries such as Canada, the United States, and Australia in concordance with
declining rates of tobacco use (Chaturvedi et al., 2013). However, although the incidence
HPV-negative OPC has decreased by 50% over the last two and a half decades, the
overall incidence of oropharyngeal cancer has increased by 28% (Chaturvedi et al.,
2011). This increase has been attributed to HPV, although it is still unclear why the virus
seems to affect the oropharynx more than other anatomical sites of the upper airway. One
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theory is that the oropharynx is more directly exposed to HPV during oral sex when
compared to other parts of the upper airway (e.g., the nasopharynx). Another theory is
that the convoluted structure of the tonsils and base of tongue provide the perfect
environment for HPV DNA to become trapped and incubate. However, more research is
clearly needed to determine why HPV-related tumours disproportionately affect the
oropharynx compared to other areas of the upper airway.
Oropharyngeal cancer also seems to disproportionately affect men. In 2009, there
were approximately 13,000 new cases of OPC in the United States, 10,500 (81%) of
which occurred in men (Jemal et al., 2013). Furthermore, it is estimated that by 2020 the
annual number of new HPV-positive OPCs will surpass the number of new cervical
cancers in the United States, roughly 85% of which will occur in men (Chaturvedi et al.,
2011). Head and neck cancer has traditionally been more common in men, and this trend
seems to be continuing as the proportion of head and neck cancers that are HPV-positive
continues to rise. However, it is still unknown why this discrepancy exists for HPVpositive head and neck cancers, considering relatively equal rates between genders for
participation in oral sex acts. In fact, within the United States, while differences by age
group do exist, it has been reported that approximately 85.4% of men and 83.2% of
women have performed oral sex (D’Souza, Cullen, Bowie, Thorpe, & Fakhry, 2014).
Introduction of the HPV Vaccine
In 2006, Health Canada, along with the Food and Drug Administration (FDA) in
the United States, approved the use of a quadrivalent HPV vaccine (Gardasil™) to
protect against HPV strains 6, 11, 16 and 18. A subsequent bivalent vaccine (Cervarix™)
was approved in 2009, this vaccine protecting against HPV strains 16 and 18 only. Since
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the HPV vaccine protects against a sexually transmitted virus, it would be most effective
if administered prior to the onset of sexual activity. In 2003, a national survey indicated
that the mean age of first sexual intercourse was 15.7 years for both males and females
(Statistics Canada, 2003). Furthermore, only 3.5% of the population had engaged in
intercourse by 13 years old (Statistics Canada, 2003). Therefore, Gardasil™ was initially
recommended for use in females between 9 and 13 years old to prevent cervical lesions.
Health Canada also recommended that females up to the age of 26 receive the vaccine as
well, even if they had already been sexually active. The efficacy of the vaccine for
preventing cervical lesions had previously been found to be greater than 95% effective
(Garland et al., 2007).
Between the years 2007 and 2009, many developed countries including Canada,
the United States, the UK, Sweden, Japan, and others introduced a publically-funded
HPV vaccination program for adolescent girls as a means to prevent HPV infection.
While the original purpose of the vaccine was to prevent the development of anogenital
cancer and genital warts in women (Garland et al., 2007), the recommended use of the
vaccine has recently expanded to include use in males (Centers for Disease Control and
Prevention, 2011). In 2009, Gardasil™ was approved for use in males as a means to
prevent genital warts (United States Food and Drug Administration, 2011). In 2010, the
United States Food and Drug Administration (FDA) added prevention of anal cancer as
another reason to vaccinate both males and females (United States Food and Drug
Administration, 2011). Finally, in 2011 the Advisory Committee on Immunization
Practices of the FDA recommended that Gardasil™ be routinely used in males aged 1112 (Centers for Disease Control and Prevention, 2011). In summary, there is strong and
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consistent support across many developed countries for the use of the HPV vaccine in
both males and females as a means to prevent anogenital cancers and genital warts.
Both of the current vaccines (i.e., Cervarix™ and Gardasil™) provide a very high
prevention rate for cervical and anal HPV 16 or 18 infections (Garland et al., 2007;
Harper et al., 2004). Although there is no high-level evidence to suggest the two vaccines
are equally effective at other anatomical sites such as the oropharynx and penis,
preliminary data supports the efficacy of the vaccine to protect against HPV infection at
other anatomical sites; blood samples of vaccinated individuals show that the immune
response is similar in males and females (Garland et al., 2007; Giuliano, Palefsky, et al.,
2011). Since the majority of HPV-related cancers are caused by strains 16 and 18, both of
the HPV vaccines may hold significant potential to prevent a large proportion of the
cancers discussed previously. As the incidence of HPV-related cancers continues to rise,
especially in men, the prevention of these cancers is becoming increasingly important.
A recent systematic review by Mariani et al. (2015) suggests that the HPV
vaccine has been extremely effective at preventing genital warts associated with HPV 6
and 11. Genital wart incidence has declined up to 92% in some populations since the
introduction of school-based HPV vaccination programs (Mariani et al., 2015).
Reductions in incidence were highest in countries with the highest vaccination rates and
in females under the age of 25 (Mariani et al., 2015). Even in the United States, where
vaccination rates are relatively low compared to other countries such as Australia, the
incidence of genital warts decreased 37.9% between 2006 and 2010 in females aged 2025 (Flagg, Schwartz, & Weinstock, 2013). The impact that the HPV vaccine is having on
HPV-related cancers caused by HPV 16 and 18 has yet to be determine due to the lag
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time between HPV infection and cancer development. The full effect of the HPV vaccine
is not anticipated to be observed at the population level until 30-50 years after the
introduction of the vaccine because of the long lag time between infection and detection
of cancer (Dasbach, Insinga, & Elbasha, 2008). However, some studies have shown that
the prevalence of HPV 16 and 18 infections has decreased since the introduction of the
vaccine (Markowitz et al., 2013; Mesher et al., 2013).
Vaccination Rates. Unfortunately, HPV vaccination rates in Canada have
remained well below the idealized target of 90% coverage for elementary school-aged
girls (Canadian Immunization Committee, 2007). In Ontario, HPV vaccine uptake was
initially below 50% when it was first introduced in 2007; however, uptake has gradually
increased to 70.2% in 2012 (Lim, McIntyre, & Wilson, 2013). Nationwide, the HPV
uptake rate for school-aged females ranges from 50% in Alberta and Manitoba to 85% in
Newfoundland, Nova Scotia and Quebec (Shearer, 2011).
While the national HPV vaccination program allows adolescent girls to receive
the vaccine free-of-charge, no such funding exists for males. Only two provinces (Alberta
and PEI) provide the vaccine to males for free. Health Canada has claimed it is more
cost-effective to vaccinate females only, citing the phenomenon of “herd immunity” as a
way to prevent HPV infections in the entire population (Canadian Immunization
Committee, 2014). However, this strategy has limitations for several reasons. First, it
does not protect men who have sex with men (MSM), even though the prevalence of
high-risk HPV is higher in this population compared to the general population at large
(National Advisory Committee on Immunization, 2012). Second, herd immunity is
ineffective at protecting males in areas where female vaccination rates are low because
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there are still sufficient numbers of unprotected females who can transmit the infection.
Lastly, when a broader range of health outcomes are considered (i.e., HPV-related
cancers in males), or when female vaccination rates are low, it may actually be more
cost-effective to provide the HPV vaccine to males (Graham et al., 2015).
Reasons for Non-Vaccination. A variety of reasons to explain the low rates of
HPV vaccination have been cited in the literature. Since the vaccine is administered at
such a young age (grades 4-8, depending on province), it is unlikely that the recipients
fully understand the reasoning behind the vaccine. Therefore, the role of the parent(s)
becomes paramount in deciding whether or not to vaccinate children. Many parents
simply do not want to talk to their adolescent children about sexually transmitted
infections; similarly, other parents feel that by vaccinating their children they are
somehow acknowledging that it is okay to act promiscuously in the future (Zimet,
Rosberger, Fisher, Perez, & Stupiansky, 2013). Follow-up studies have proven this fear
to be groundless, as there are no differences in sexual behaviour (Forster, Marlow,
Stephenson, Wardle, & Waller, 2012; Hansen et al., 2014) or attitudes towards cervical
cancer screening (Mather, McCaffery, & Juraskova, 2012) between vaccinated and nonvaccinated females.
Safety concerns are frequently cited as another reason for non-vaccination (Reiter
et al., 2013). Although many high-level scientific studies have proven the HPV vaccine is
safe, fear-inducing stories on the Internet and in the popular media have much more
influence over the general population than scientific journals. The so-called “antivaccination” movement, which has become increasingly prevalent in recent years, has
provided strong opposition to the HPV vaccine. This anti-vaccination movement has
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prospered by spreading misinformation, and in some cases, outright falsehoods over the
Internet. Ongoing efforts to educate the general population must move beyond scientific
publications and into the mainstream if they are to be effective as educational resources.
Educational efforts must also provide accurate information that is easy to understand, as
well as serving to highlight the risks of non-vaccination.
Finally, one of the biggest reasons for non-vaccination is the lack of knowledge
people have regarding HPV, HPV risk factors and its potential morbidities, and the HPV
vaccine itself. Not knowing enough about the vaccine and not knowing boys could get
the HPV vaccine are frequently cited reasons for non-vaccination (Donahue, Stupiansky,
Alexander, & Zimet, 2014; Zimet, Weiss, Rosenthal, Good, & Vichnin, 2010). Therefore,
having an accurate understanding of the risks associated with contracting an HPV
infection, in addition to having accurate knowledge of the HPV vaccine, are key factors
in one’s decision to become vaccinated. Therefore, issues related to awareness and
knowledge of HPV will be explored further in the sections to follow.
HPV Awareness and Knowledge as an Important Factor in Prevention
Despite the extremely high prevalence of HPV infection, according to existing
data, opportunities for infection prevention and subsequent prevention of the many
associated morbidities still exist. The HPV vaccine will certainly play a large role in the
prevention strategies of many countries; however, broad-focused sexual education and
information on behavioural factors are equally important factors in combatting the high
prevalence of HPV infection. The decision to engage in health-protective behaviours is
also borne of having an accurate understanding of the potential consequences involved
with engaging in high-risk sexual behaviour. In the context of HPV infection, behavioural
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factors such as the decision to initiate new sexual relationships, use of protection during
sex, and the type of sexual activities in which one participates almost certainly is
moderated by one’s awareness, knowledge, and perceived risk of the virus. Many health
behaviour theories confirm the importance of awareness and knowledge (sometimes
referred to as information) as a necessary precursor to health-protective behaviour
(Bandura, 2004; Fisher, 2012). These same principles apply in the decision making
process of those considering HPV vaccination for themselves or their children, as
previous studies have shown a relationship between HPV knowledge levels and vaccine
uptake (Chan, Chan, Ng, & Wong, 2012).
From a population standpoint, it is known that the prevalence of HPV infection is
highest among people under the age of 25. It is also known that 85% of males and 82% of
females will have engaged in sexual activity by the time they are 25 years of age
(Chandra, Mosher, Copen, & Sionean, 2011), making this life stage an extremely
important time period for the development of sexual activity behaviours. Therefore,
having an accurate sense of what this general young adult population (age 18-24) knows
about HPV, HPV-related cancers, and the HPV vaccine has important implications for
educators, policy makers, and health care providers tasked with preventing HPV-related
morbidity and mortality. As such, a summary of current awareness and knowledge levels
will be discussed in the following section.
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Awareness and Knowledge of HPV, HPV-Related Cancers, and the HPV Vaccine
For the purposes of the study to be described in following sections, the term
“awareness” refers to one’s yes/no acknowledgment of ever having heard of something.
The term “knowledge” refers to one’s understanding of specific facts relating to the
person, place, or thing in question. Therefore, awareness is a necessary precursor for
knowledge. That is to say, one cannot have knowledge of HPV without first having heard
of HPV. However, one can be aware of HPV without having any knowledge of it, as
knowledge exists on a continuum ranging from no knowledge to an expert level of
understanding.
Many studies have evaluated the awareness and knowledge levels of HPV in
various populations. HPV awareness levels can range from as low as 10% in a large
sample of over 10,000 Danish men of all ages (Nielsen, Munk, Liaw, & Kjaer, 2009) to
over 95% of the population in samples of female university students (Dillard & Spear,
2011). Similar variability has been reported for HPV vaccine awareness, ranging from
63% awareness in a sample of American males (Reiter, Brewer, & Smith, 2010) to 87%
awareness in the general population (Ragin et al., 2009) to over 95% in populations of
female university students (Bendik, Mayo, & Parker, 2011).
Knowledge. Knowledge of HPV and the HPV vaccine is also highly variable
depending on the population studied. In a systematic review that assessed HPV
knowledge in over 20,000 individuals across many countries, correct responses to
questions regarding common facts about HPV varied widely. For example, between 868% of respondents knew HPV was a risk factor for cervical cancer, between 10-73% of
respondents knew that HPV can be asymptomatic, and between 47-87% of respondents
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knew HPV is sexually transmitted (Klug, Hukelmann, & Blettner, 2008). In general, it
appears that women tend to know more about HPV than do men (Klug et al., 2008),
however, the fact remains that many women also have a very limited understanding of
HPV and how it relates to cancer (Chan et al., 2012). Since the introduction of the HPV
vaccine in 2007, it appears that knowledge and awareness of the virus is increasing,
however, knowledge gaps still remain (Gerend & Magloire, 2008).
Influence of Demographic Variables
Many studies have also shown significant racial and ethnic differences in HPV
awareness and knowledge. In a study by Joseph et al. (2014), only 42% of AfricanAmerican individuals identified HPV as a risk factor for cervical cancer, compared to
90% of Caucasian individuals. Racial disparities in awareness and knowledge of HPV
and the HPV vaccine also have been reported in samples of women only (Gelman,
Nikolajski, Schwarz, & Borrero, 2011). Differences in knowledge between publicly and
privately insured women have also been reported, with significantly higher knowledge
levels observed in privately insured women, suggesting a potential link between socioeconomic status (SES) and HPV knowledge (Kennedy, Osgood, Rosenbloom, Feinglass,
& Simon, 2011). Socio-economic status may be confounded by other factors such as
cultural background, level of education, and ethnicity, as each of these variables has been
associated with differences in HPV knowledge levels (Joseph et al., 2014; Klug et al.,
2008; Marlow, Zimet, McCaffery, Ostini, & Waller, 2013; Waller, McCaffery, &
Wardle, 2004).
Furthermore, people who are younger, female, and who have more education are
significantly more likely to have heard of the HPV vaccine (Gollust, Attanasio, Dempsey,
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Benson, & Fowler, 2013). Increases in awareness and knowledge are also strongly
correlated with the intention to receive the HPV vaccine (Kang & Kim, 2011; Krawczyk,
Stephenson, Perez, Lau, & Rosberger, 2013), engage in health-protective behaviours
(Pask & Rawlins, 2015), and vaccine uptake (Donadiki et al., 2013; Laz, Rahman, &
Berenson, 2013).
Summary
HPV infection is extremely prevalent in sexually active 18-25 year olds. As noted
previously, many HPV infections are benign and clear spontaneously. However, infection
with HPV strains 6 or 11 may lead to anogenital warts and infection with certain “high
risk” strains, namely HPV 16 or 18, may lead to the development of cancers in the upper
airway (most commonly the oropharynx) or anogenital tract. The incidence of HPVpositive cancer is increasing, especially in men. The introduction of the HPV vaccine in
2007 was an important step forward in preventing these cancers, however, vaccination
uptake remains low in certain populations. This low uptake is true even for advanced
countries whose populace is generally well educated and economically prosperous.
Awareness and knowledge of HPV, HPV risk factors and associated morbidities, and the
HPV vaccine is strongly associated with both vaccine uptake and engaging health
protective behaviours. Therefore, it is essential that an accurate measure is taken of
awareness and knowledge of HPV in the population at highest risk for HPV infection;
that is, those who are under the age of 25, those who may have an increased likelihood of
engaging in sexual activity, and those who are eligible for HPV vaccination. This will
allow identification of knowledge gaps related to HPV and the HPV vaccine in order to
inform current and future prevention and education interventions.
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Statement of Problem
Based on existing data, HPV infection is an extremely prevalent health issue.
Further, HPV-related morbidities have become increasingly prevalent in recent decades
(Auluck et al., 2010; Bosch et al., 2013; Chaturvedi et al., 2011; Jemal et al., 2013;
Judson et al., 2006). This observation led to the introduction of the HPV vaccine in 2007.
Research has shown that young adults in Canada and other developed countries with
established HPV vaccination programs generally have high awareness levels of HPV and
the HPV vaccine. However, there is wide variation in HPV knowledge levels (i.e., what
people actually know about it) depending on the population studied. Furthermore, few
studies have assessed knowledge of HPV or the HPV vaccine as it relates to non-cervical
cancers, particularly in respect to head and neck cancer in general and oropharyngeal
cancer in specifics. Due to the importance of knowledge as a precursor for the prevention
of HPV infection through health-protective behaviours (including vaccination),
understanding the awareness and knowledge levels of young adults most at risk for HPV
infection becomes paramount.
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Objectives of the Current Study
Thus, the objectives of the current study are to:
1) Assess awareness and knowledge of HPV, HPV-related cancer, and the HPV
vaccine in a population of young adult university students;
2) Identify knowledge gaps in young adults' understanding of HPV, OPC and the
HPV vaccine through a series of "true/false/I don't know" questions; and
3) Identify demographic variables that may lead to greater or lesser levels of
awareness and knowledge specific to the HPV-related topics identified above.
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CHAPTER 2
Method
Participants
In total, 1005 individuals participated in this study. Participants ranged in age
from 18 years, 0 months to 30 years, 11 months (mean = 20.92 years). 711 participants
were female, 292 were male, and 2 participants self-identified as being of non-binary
gender. Female participants were slightly younger, with a mean age of 20.84 years (range
= 18-30) when compared to their male counterparts who had a mean age of 21.12 years
(range = 18-30). All participants were current students at the University of Western
Ontario (UWO) main campus. Although variability in representation existed, the sample
population included students from every faculty at the University of Western Ontario
including Arts & Humanities, Business, Education, Engineering, Health Sciences,
Information and Media Studies, Law, Medicine & Dentistry, Music, Science, and Social
Science. A complete breakdown of the number of participants from each faculty can be
found in Table 1.
All participants were initially recruited in one of three ways:
1) A member of the research team approached a potential participant in a common
area of the university campus (University Community Centre, Recreation Centre,
building lobbies, etc.) and provided a brief verbal description of the study. If
interested, the potential participant provided their email address. Within 24 hours,
the letter of information for the study, which contained a link to the online survey,
was emailed to them. A reminder email was sent to all participants who had not
responded after 7 days since their original recruitment. Interested participants
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could also choose to complete the survey at the time of contact with the researcher
using a Blackberry Playbook™ tablet connected to Wi-Fi internet.
2) After obtaining permission from class instructors, verbal announcements were
made in various university courses at the end of lectures. These announcements
consisted of a short description of the study objectives and protocol lasting
approximately two minutes. In some instances, a visual slide containing similar
information about the study in text format was projected simultaneously. Potential
participants were instructed to email the researcher directly if interested. Upon
receiving emails from these potential participants, the letter of information for the
study along with a direct link to the online survey were sent back to them within
24 hours.
3) In conjunction with recruitment Method 2, and with the course instructor’s
permission, an announcement was posted to the OWL course website of the
classes in which a verbal announcement was made. This announcement contained
a reminder about the verbal announcement made in class and an attached letter of
information with a link to the survey.
Prior to the initiation of this research study, the Ethics Review Board at The
University of Western Ontario approved this protocol; ERB Approval #105733 (see
Appendix A).
Inclusion Criteria. In order to be included in this study, participants had to be
currently registered as students at the University of Western Ontario. Both undergraduate
and graduate students were included in the study. All participants were required to be
between the ages of 18 and 30 and English speakers. This population was chosen because
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they represent the age cohort with the highest prevalence of both cervical and oral cavity
HPV infection (D’Souza, Agrawal, Halpern, Bodison, & Gillison, 2009; Sellors et al.,
2000; Steinau et al., 2014).
Exclusion Criteria. Individuals who were younger than 18 years of age or greater
than 30 years of age were excluded from the study. These exclusion criteria were based
on the judgement that individuals over the age of 30 represent a different cohort than that
of traditional “university aged” young adults. Both males and females over age 30 also
fall outside of the age group that is at the highest risk of acquiring an HPV infection
(Giuliano, Lee, Fulp, Villa, Lazano, et al., 2011; Sellors et al., 2000). Additionally,
individuals over the age of 30 were either above or near the upper limit of the
recommended age of vaccination when the HPV vaccine was first introduced in 2007
(Shefer et al., 2008) and, therefore, may have less knowledge of HPV compared to those
who were exposed to the national HPV vaccination program and its’ related advertising
campaign (Donders et al., 2009).
Due to the method in which participants were recruited and data were collected
(i.e., posted on OWL for all members of a class), some survey respondents were over the
age of 30 (n=19). Some respondents also failed to answer one or more sections of the
survey (n=26); for this reason, these respondents were removed from the data set prior to
data analysis and are not included in the final number of participants for whom data were
analyzed.
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Procedure
The study consisted of a cross-sectional, self-administered, web-based survey
design. For this investigation, a questionnaire was designed and utilized for data
collection purposes with the intent of assessing awareness and knowledge of the Human
Papillomavirus (HPV), Oropharyngeal Cancer (OPC), and the HPV vaccine in a sample
of university students. The researcher-designed questionnaire was designed and
administered through the website Surveymonkey.com.
All individuals who were recruited for the study were provided with a letter of
information (see Appendix B) either via email or through OWL announcements. A link to
the online survey was provided at the end of the letter of information. In compliance with
ethical requirements, informed consent was indicated by the participant’s voluntary
completion of the questionnaire. This procedure of obtaining informed consent was
explicitly stated in the letter of information. The letter of information also informed
potential participants of the purpose of the study, the voluntary nature of one’s
participation, the benefits and risks of participating in the study, and the compensation
they may be eligible for by participating in the study. The entire survey typically took
between three and six minutes to complete.
Compensation. At the conclusion of the online survey, participants had the option
to navigate to a separate web page where they could enter their email address into a draw
for a $50 gift card. A separate web page was used for this draw in order to ensure that
participant responses were not linked to their email addresses, thus, maintaining
anonymity. Participants were also informed in the letter of information that enrollment
into the gift card draw was not dependent on completing the survey. Therefore,
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participants who did not answer one or more questions were still eligible for
compensation.
Measurement Instrument/Questionnaire
The questionnaire utilized for this study was a 42-item, self-designed survey
consisting of four sections: Demographic Information, HPV Awareness and Knowledge,
OPC Awareness and Knowledge, and HPV Vaccine Awareness and Knowledge.
Individual survey items were adapted and modified from a total of seven previous
studies. The questionnaire was designed specifically for this project. Five of these
studies focused on knowledge and awareness of HPV and the HPV vaccine (Bowyer,
Marlow, Hibbitts, Pollock, & Waller, 2013; Gerend & Magloire, 2008; Pelullo, Di
Giuseppe, & Angelillo, 2012; Ragin et al., 2009; Ramirez, Ramos, Clayton, Kanowitz, &
Moscicki, 1997), while the other two identified risk factors for oropharyngeal cancer
(Gillison, D’Souza, et al., 2008; Nichols et al., 2013). Data from the two OPC risk factor
studies were transformed into a series of true/false/I don’t know questions in order to test
participants’ knowledge of OPC.
Individual items included in the questionnaire were adopted from the
aforementioned literature and selected for inclusion in the present study based on their
relevance to the objectives of the study. While some of the questionnaire items were
adapted from previous studies that used a validated survey tool for assessing HPV
knowledge, the questionnaire used for this study had not been previously validated.
However, prior to the initiation of data collection, 10 individuals (5 graduate students and
5 undergraduate students) examined the questionnaire for face validity. The complete
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questionnaire and the published studies from which they were sourced can be found in
Appendix C.
Demographic Information. The demographic section consisted of seven items:
participant’s age, gender, ethnicity, current level of education, faculty in which they were
enrolled, HPV vaccination status, and primary source of HPV information. Age was
measured in years plus the closest number of additional months since birthday (e.g., 20
years, 7 months). Ethnicity categories were sourced from the 2006 Canadian census and
participants were able to specify ‘other’ if they did not identify with any of the ethnic
categories listed (Statistics Canada, 2006). Current level of education was assessed based
on year of study (e.g., first, second, third, fourth, fifth year undergraduate or graduate
student) and all graduate students were considered to be in the same category of
education level, regardless of what year of study they were in. HPV vaccination status
was assessed by number of doses of the vaccine received; participants could also select
“not vaccinated” or “I don’t know” in reference to vaccination status.
HPV Awareness. HPV awareness was assessed with the single yes/no question,
“Prior to this survey, have you ever heard of the Human Papillomavirus (HPV)?”. If the
participant answered ‘yes’ to this question, they would proceed to the HPV knowledge
questions. If the participant answered ‘no’ they would go directly to the next section
which addressed OPC awareness and knowledge. This method of question administration
assumed that if the participant had never previously heard of HPV, they would also know
nothing about it. Therefore, to prevent these participants from guessing and potentially
skewing the data, those participants who had not heard of HPV before never had access
to the HPV knowledge questions.
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Perceived Concern of HPV Infection. All participants were asked to rate their
personal level of concern about potentially becoming infected with HPV. This rating was
made using an equal-appearing interval (EAI) scale that ranged from 1 to 5. A response
of 1 meant that the participant was “not concerned at all”, while a response of 5 indicated
that the participant was “extremely concerned” about becoming infected with HPV.
Self-Perceived HPV Knowledge. All participants also were asked to rate their selfperceived level of HPV knowledge on a second EAI scale that again ranged from 1 to 5.
A response of 1 meant the participant believed that they knew “nothing” about HPV, with
a response of 5 representing “very much/expert”, thus, indicating that the participant
thought their knowledge levels were considerable.
HPV Knowledge. The HPV knowledge section consisted of 17 statements
regarding established facts about HPV and HPV risk factors. After reading each
statement, participants could choose the responses ‘true’, ‘false’, or ‘I don’t know’. The
‘I don’t know’ option was once again included in an effort to reduce or prevent
participants from guessing; participants were explicitly instructed to choose this option if
they would consider their answer to be a guess.
Oropharyngeal Cancer Awareness. OPC awareness was assessed with a single
“yes/no” question: “Prior to this survey, have you ever heard of oropharyngeal cancers
(cancer of the throat, base of tongue, soft palate, and/or the tonsils?)”. Similar to the
previous section, if the participant answered ‘yes’ to this question, they would proceed to
the OPC knowledge questions. Again, if they answered ‘no’, they would go directly to
the next section (HPV vaccine awareness and knowledge).
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Self-Perceived Concern of Developing Oropharyngeal Cancer. All participants
were asked to rate their level of concern about developing oropharyngeal cancer using a
5-point EAI scale. A response of 1 meant that the participant was “not concerned at all”,
while a response of 5 meant that the participant was “extremely concerned” about
developing OPC.
Self-Perceived Oropharyngeal Cancer Knowledge. Similarly, all participants
were asked to rate their self-perceived level of oropharyngeal cancer knowledge on an
EAI scale that again ranged from 1 to 5. A response of 1 meant that the participant
thought they knew “nothing” about oropharyngeal cancer, while a response of 5 (“very
much/expert”) indicated that the participant thought they had considerable knowledge.
Oropharyngeal Cancer Knowledge. The OPC knowledge section consisted of six
questions for which either a True/False or “I don’t know” response was required.
Questions in this section addressed OPC risk factors (e.g., “Smoking tobacco increases
the risk of developing oropharyngeal cancer”), incidence trends (e.g., “The number of
new oropharyngeal cancer cases per year in Canada is increasing”), and general OPCrelated facts (e.g., “Both men and women can get oropharyngeal cancer”).
HPV Vaccine Awareness. This section followed the same format as the previous
two sections. HPV vaccine awareness was assessed with the yes/no question: “Prior to
this survey, have you ever heard of the HPV vaccine (brand names Gardasil™ or
Cervarix™)?”. An answer of ‘no’ to this question would take the participant to the end of
the survey. If the participant answered ‘yes’, they would proceed to the HPV vaccine
knowledge questions before finishing the survey.
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HPV Vaccine Knowledge. The HPV vaccine knowledge section consisted of five
statements to which participants could once again respond with one of three options:
‘true’, ‘false’, or ‘I don’t know’. Items in this section included statements regarding the
vaccine’s function (e.g., “The HPV vaccine protects against cervical cancer”) and who
can receive the vaccine (e.g. “Men cannot obtain the HPV vaccine”).
Data Analysis
Raw data in the form of individual survey responses were exported from
Surveymonkey.com into a Microsoft® Excel (2011) spreadsheet. Descriptive statistics
(i.e., means, medians, standard deviations, and ranges) were calculated for the
demographic data. Descriptive statistics were also used to summarize the responses to the
three awareness questions (e.g., total number of people who had heard of HPV, OPC, and
the HPV vaccine).
A knowledge score for each of the three knowledge sections was generated using
the number of correct responses within each section. Therefore, a participant’s
knowledge score could range from 0-17 in the HPV knowledge section, 0-6 in the OPC
knowledge section, and 0-5 in the HPV vaccine knowledge section. All responses of ‘I
don’t know’ were counted as an incorrect response. Participants who skipped a
knowledge section due to an answer of ‘no’ on the preceding awareness question were
given a knowledge score of zero for that section. This followed the logic that if, for
example, participants had no awareness of HPV, then they also would not have
knowledge related to it. Upon completion, the number of correct responses to all 28
knowledge questions was summed to create a total knowledge score for each participant.
Hence, total knowledge scores could range from 0-28.
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Descriptive statistics were also used to report the percentage of participants who
answered each individual question correctly, allowing for the identification of specific
knowledge gaps in this sample.
Overall levels of knowledge were determined using the cumulated mean scores of
each participant for each of the three knowledge categories. A mean total knowledge
score was calculated by determining the average number of correct responses to all 28
knowledge questions from all participants. Comparisons were made between different
demographic groups using these mean knowledge scores.
Comparison of Knowledge Scores Between Genders.
Four independent t-tests were performed using SPSS 16.0 for Windows (SPSS
Inc., 2008) in order to compare the HPV, OPC, HPV Vaccine, and Total mean
knowledge scores between men and women. An a priori alpha level of p < 0.05 was used
in order to determine significance. However, because four t-tests were performed, the
alpha level of 0.05 was divided by four in order to further decrease the probability of a
type 1 error (i.e., finding a significant difference when, in fact, there is not one).
Therefore, an a priori significance level of 0.0125 was used to test for significance.
Results of these comparisons will be presented in Chapter 3.
Correlation Analyses of Knowledge Scores
A Pearson’s product-moment correlation coefficient was performed using SPSS
16.0 for Windows (SPSS Inc., 2008) in order to determine potential relationships
between the four knowledge scores (HPV, OPC, HPV vaccine and Total). Male and
female knowledge scores were correlated separately. Demographic variables such as age
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and year of study were also included in the correlational assessment relative to the scores
obtained.
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CHAPTER 3
Results
Response Rates
In total, 454 individuals were approached directly in common areas of the
university using Recruitment Method 1. Of these 454 people, 198 completed the survey
at the time of contact using a tablet provided by the researcher. The remaining 236
individuals provided their email address and asked to have the survey sent to them, of
which 119 (50.4%) eventually completed it. Twenty people refused participation
altogether. Overall, 317 (69.8%) of the 454 people approached using this method of
recruitment completed the survey.
In addition to the recruitment method outlined above, 45 class announcements
were made in various courses across campus using Recruitment Method 2. Based on the
number of students enrolled in each class, and assuming all students were present, it was
estimated that 4,985 students were exposed to this method of recruitment. In total, 733
responses were collected using this method of recruitment, equating to a response rate of
14.7%.
Therefore, based on both methods of recruitment, 5439 students were exposed to
at least one method of recruitment and 1050 responses were gathered, bringing the
overall response rate to 19.3%.
Participant Response Exclusions
Forty-five of the 1,050 responses were excluded from final data analysis. Of
these, 19 were excluded due to being 30 years of age or older, 3 were excluded for
missing responses on one section of the survey, and 23 were excluded due to missing
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responses on multiple sections of the survey. Therefore, a total of 1,005 responses were
included in final data analysis. Thus, the following results are based on the responses of
1,005 participants.
Demographic Information
Gender: In total, 711 females (mean age = 20.84 years, range = 18 years, 0
months – 30 years, 0 months), 292 males (mean age = 21.12 years, range = 18 years, 0
months – 30 years, 10 months), and 2 non-binary (mean age 20.5 years) individuals were
included in final data analysis. “Non-binary” is a term for individuals with any gender
identity that does not conform to the mutually exclusive categories of male and female,
including transgender, agender, bigender, genderfluid, and others. The proportion of
males (29%) to females (71%) in this study differed slightly from the overall full-time
undergraduate and graduate student body at Western, which is reported to be comprised
of 45% males and 55% females. See Appendix D for a complete breakdown of Western’s
student body by gender and program of study. Non-binary individuals were not included
in gender comparisons; however, they were included in other demographic comparisons
(year of study, program of study, etc.).
Age. The mean age of all 1,005 participants was 20.92 years (range = 18 years, 0
months – 30 years, 10 months). 13 participants did not specify their age. The age
distribution of participants is displayed in Figure 1.
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Figure 1. Age of Participants
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Table 1. Demographic Data of Participants

Variable
Women n (%)
Number of Participants
711 (71)
Age (years)
Mean 20.84
Ethnicity
n (% of total)
Caucasian
522 (71)
Chinese
55 (70)
South Asian
44 (73)
Black
17 (74)
Filipino
6 (100)
Aboriginal
1 (100)
Latin American
10 (77)
Southeast Asian
10 (83)
Arab
8 (44)
West Asian
1 (100)
Korean
8 (80)
Japanese
2 (100)
Other
27 (66)
a
Year of Study
n(%)
st
1 year undergrad
94 (69)
nd
2 year undergrad
173 (75)
rd
3 year undergrad
134 (71)
th
4 year undergrad
152 (68)
th
5 year undergrad
25 (52)
Graduate student
129 (77)
Faculty of Participant’s Enrollmentb n(%)
Arts & Humanities
35 (78)
Business
39 (48)
Education
0 (0)
Engineering
25 (30)
Health Sciences
307 (84)
Information and Media Studies
54 (90)
Law
27 (73)
Music
39 (71)
Schulich Medicine and Dentistry
6 (33)
Science
81 (660)
Social Science
98 (73)
*2 participants self-identified as non-binary gender.
a
7 participants did not indicate their year of study.
b
1 participant did not indicate their faculty of enrolment.

Men n (%)
292 (29)
Mean 21.12
n (%)
218 (29)
23 (30)
15 (27)
6 (26)
0 (0)
0 (0)
3 (23)
2 (17)
10 (56)
0 (0)
2 (20)
0 (0)
12 (34)
n(%)
43 (31)
58 (25)
56 (29)
72 (32)
23 (48)
38 (23)
n(%)
9 (22)
43 (52)
1 (100)
59 (70)
57 (16)
6 (10)
10 (27)
16 (29)
11 (66)
42 (33)
37 (27)

Total
1005*
Mean 20.92
n (%)
740 (74)
79 (8)
60 (6)
23 (2)
6 (.6)
1 (.01)
13 (1)
12 (1)
18 (2)
1 (.01)
10 (1)
2 (.02)
40 (4)
n(%)
137 (14)
232 (23)
190 (19)
224 (22)
48 (5)
167 (17)
n(%)
45 (4.5)
82 (8)
1 (.001)
84 (8)
364 (36.5)
60 (6)
37 (4)
55 (5)
18 (2)
123 (12)
135 (13.5)
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HPV Vaccination Status. Based on data gathered, 412 (40.9%) respondents had
received at least one dose of the HPV vaccine. Vaccination rates were much higher in
females, with 51.6% of females (n=367) and 15.4% (n=45) of males having received at
least 1 dose of the vaccine. Thirty percent of males (n=85) and 9.8% of females (n=67)
were unsure of their vaccination status; only participants who explicitly indicated they
had received at least one dose of the vaccine were counted as having been vaccinated.

Figure 2. Participant Vaccination Status
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HPV knowledge Sources
As part of this survey study, participants were asked to indicate where in the past
they had obtained information regarding HPV. Participants were permitted to select more
than 1 option, if applicable. Results from this question are presented in Figure 3.
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Figure 3. HPV Knowledge Sources
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HPV Awareness
Data revealed that 92.94% (n=933) of participants had heard of HPV prior to their
completion of this survey. 5.07% (n=51) of participants had not heard of HPV prior to
this survey. HPV awareness was slightly higher in females (95.07%) than in males
(87.33%). Twenty-one (2.09%) additional participants did not respond to this question.
However, those who left the awareness question blank were still able to answer the HPV
knowledge questions.
Perceived Concern of HPV Infection
All participants were asked to rate their perceived level of concern specific to
becoming infected with HPV using a 5-point Likert style scale with 1 indicating the
participant was “not concerned at all” and 5 indicating that they were “extremely
concerned”. Data revealed that the majority of participants (90.4%) rated their level of
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concern as a 3, or “moderately concerned” or lower. 72 (7.1%) participants rated their
level of concern as a 4, or “significantly concerned” and 23 (2.2%) participants rated their
level of concern as a 5, or “extremely concerned”. One participant did not respond to this
question. A complete breakdown of responses is shown in Figure 4.

Figure 4. Perceived Level of Concern about HPV Infection
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Self-Perceived HPV Knowledge
All participants also were asked to rate their self-perceived level of HPV
knowledge using a similar 5-point scale with 1 representing no knowledge and 5
representing an expert level knowledge. Data indicated that the majority of respondents
(51.3%) perceived themselves as having “very little” knowledge of HPV, that is, a scaled
response of 2. A complete breakdown of participant responses to this question is shown
in Figure 5.
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Figure 5. Self-Perceived HPV Knowledge Levels

Self-Perceived HPV Knowledge Levels
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HPV Knowledge
In total, 954 participants (259 males, 693 females, 2 non-binary) fully completed
the HPV knowledge section of the survey. Fifty-one participants were excluded from this
section because they had never heard of HPV before. Responses to each knowledge
question provided in the survey are summarized in Figure 6.

0%

HPV Knowledge Questions

Q17) Using an oral contraceptive
protects me from becoming infected…

Q16) Having sex at an earlier age
increases the risk of getting HPV

Q15) One can become infected with
HPV by having unprotected anal sex

Q14) Using condoms during
intercourse completely protects one…

Q13) One can become infected with
HPV by having unprotected oral sex

Q12) Having a higher number of
sexual partners increases the risk of…

Q11) HPV infection can cause anal
cancer

Q10) HPV usually does not need any
treatment; it usually goes away on…

Q9) HPV infection can cause
HIV/AIDS

Q8) HPV infection can cause genital
warts

Q7) HPV can cause oropharyngeal
cancer

Q6) HPV is the main cause of cervical
cancer

Q5) There are many different types of
HPV

Q4) Men cannot get HPV

Q3) A person could have HPV for
many years without knowing it

Q2) HPV is rare in Canada

Q1) HPV is a sexually transmitted
infection

Participant Response Distribution (n=954)

43

Figure 6. HPV Knowledge Questions

HPV Knowledge Questions and Response Distribution
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HPV Knowledge Scores. As part of data analysis, HPV “knowledge scores” were
generated. HPV knowledge scores were calculated by summing the number of questions
answered correctly in this section for each participant. Therefore, HPV knowledge scores
could range from 0-17. Of the 954 participants who completed the knowledge section, the
mean HPV knowledge score was 10.54 out of 17 (SD = 3.44, Range = 0-17, Median =
11). Knowledge scores were slightly higher for females (10.62, SD = 3.33, Range = 0-17,
Median = 11) compared to males (10.39, SD = 3.68, Range = 0-17, Median = 11).
Oropharyngeal Cancer (OPC) Awareness
Specific to cancer awareness, 77.51% (n=779) of participants reported having
heard of OPC prior to their completion of this survey; 21.29% (n=214) of participants
had never heard of oropharyngeal cancer previously. Further, 1.19% (n=12) of
participants did not respond to this question. OPC awareness was approximately 7%
higher for females than males, with 78.89% of females and 71.92% of males indicating
they were aware of OPC prior to the survey.
Self-Perceived Concern of Developing Oropharyngeal Cancer
All participants were asked to rate their perceived level of concern about
becoming infected with HPV, again, using a 5-point scale. Most participants indicated
they were 1) “not concerned at all” (n=368) or 2) “a little concerned” (n=358). One
participant did not respond to this question. A complete breakdown of responses is shown
in Figure 7.
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Figure 7. Level of Concern About Developing OPC
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Self-Perceived OPC Knowledge
All participants were asked to rate their self-perceived level of OPC knowledge
with a 5-point scale. Data revealed that the vast majority of participants either knew
“nothing” (n=423) or only “a little bit” (n=443); 138 (13.7%) participants indicated they
had a moderate amount of knowledge or above. One participant did not respond to this
question. A complete breakdown of responses is shown in Figure 8.
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Figure 8. Self-Perceived OPC Knowledge Levels

Number of Responses
(n=1004)

Self-Perceived OPC Knowledge Levels
500

423

443

400
300
200

106

100
0
1) Nothing

30

2

2) A Little bit 3) A Moderate 4) Quite a bit
5) Very
Amount
Much/Expert
Knowledge Level

OPC Knowledge
In total, 791 participants (576 females, 214 males, 1 non-binary) completed this
section of the survey. Scores could range from 0-6. Interestingly, 214 participants
(21.29%) were excluded from this section because they had never heard of OPC before.
A summary of the response distribution for each OPC knowledge question is presented in
Figure 9.
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Figure 9. OPC Knowledge Questions and Responses
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OPC Knowledge Scores. Similar to data analyses for the HPV knowledge section
of the survey, OPC knowledge scores also were generated by summing the number of
correct responses for each participant in this section. OPC knowledge scores could range
from 0-6. Of the 791 participants who completed this section, the mean OPC knowledge
score was 3.69 out of 6 (SD = 1.49, Range = 0-6, Median = 4). Once again, knowledge
scores were slightly higher for females (3.70, SD = 1.45, Range = 0-6, Median = 4) when
compared to males (3.67, SD = 1.57, Range = 0-6 Median = 4).
HPV Vaccine Awareness
Fully 87.86% (n= 883) of participants indicated that they had heard of the HPV
vaccine prior to this survey. Vaccine awareness was 17.28% higher for females (92.97%)
than for males (75.69%). However, 119 (11.84%) participants (49 females, 69 males, 1
non-binary) had never heard of the HPV vaccine prior to their participation in this study
and three participants did not respond to this question.
HPV Vaccine Knowledge
In total, 886 participants completed the HPV vaccine knowledge section (662
female, 223 male, 1 non-binary). 119 participants were excluded from this section
because they had never heard of the HPV vaccine before. A summary of the response
distribution for each HPV vaccine knowledge question is presented in Figure 10.
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Figure 10. HPV Vaccine Knowledge Questions and Responses
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HPV Vaccine Knowledge Scores. Once again, HPV vaccine knowledge scores
were generated by summing the number of questions answered correctly in this section
for each participant. Vaccine knowledge scores could range from 0-5. Of the 886
participants who completed this section, the mean vaccine knowledge score was 2.32 out
of 5 (SD = 1.23, Range = 0-5, Median = 2). The mean HPV vaccine knowledge scores
were slightly higher for females (2.33, SD = 1.18, Range = 0-5, Median = 2) compared to
males (2.29, SD = 1.38, Range = 0-5, Median = 2).
Total Knowledge Scores
Total knowledge scores for participants were calculated by summing each
individual’s number of correct responses from all three knowledge sections. Therefore,
total knowledge scores could range from 0-28. The mean total knowledge score for all
participants was 14.95 out of 28 (SD = 6.12, Range = 0-28, Median = 15). Data revealed
that females had higher total knowledge scores (15.51, SD = 5.59, Range = 0-28, Median
= 16) compared to males (13.66, SD = 7.04, Median = 14). Given that participants could
access each section’s knowledge questions only if they answered “yes” to the preceding
awareness question, not all participants had access to all 28 knowledge questions.
Therefore, participants who answered ‘no’ to one or more awareness questions could not
achieve a perfect total knowledge score (i.e., a score of 28). However, this is consistent
with the logic used throughout the survey that awareness is a necessary precursor for the
assessment of one’s knowledge.
Demographic Factors, Awareness, and Knowledge
Year of Academic Study. Participants were separated into their respective year of
university education, as determined by the demographic section of the questionnaire.
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Seven participants did not specify their year of education and were, therefore, not
included in this summary. Awareness levels and mean knowledge scores were calculated
for each cohort and for each section of the questionnaire (HPV, OPC, and HPV vaccine).
Awareness levels were calculated by determining the percentage of participants in each
cohort who had previously heard of HPV, OPC, and the HPV vaccine, respectively.
Mean knowledge scores for each section were generated using only the responses of
participants whom had either answered ‘yes’ to the corresponding awareness question or
left the awareness question blank, thereby granting them access to the knowledge
questions. That is, participants who answered ‘no’ to the question “have you ever heard
of HPV prior to this survey?” were not included in the calculation of mean HPV
knowledge scores. This rule applied for the OPC and HPV vaccine sections as well.
Results are shown in Table 2.
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Table 2. Awareness Levels and Mean Knowledge Scores by Year of Education

Year of
Study
1st Year
N = 137

nd

2
N = 232

HPV
Awareness

HPV
Knowledge
(Possible
Range = 0-17)

OPC
Awareness

OPC
Knowledge
(Possible
Range = 0-6)

HPV
Vaccine
Awareness

87.6%

Mean = 9.91

67.9%

Mean = 3.60

80.3%

93.97%

Vaccine
Knowledge
(Possible
Range =
0-5)
Mean = 2.20

SD= 3.66

SD = 1.705

SD = 1.232

N=127

N= 97

N=110

Mean = 10.04

70.26%

Mean = 3.47

88.36%

Mean =

SD = 3.10

SD = 1.467

2.092

N = 221

N = 167

SD = 1.127
N = 205

rd

3
N = 190

92.93%

Mean = 10.46

75.79%

Mean = 3.77

90.00%

Mean =

SD = 3.514

SD = 1.503

2.5058

N = 181

N = 145

SD = 1.313
N = 172

th

4
N = 224

93.75%

Mean = 10.77

83.48%

Mean = 3.86

87.50%

Mean =

SD = 3.558

SD = 1.3882

2.4141

N = 214

N = 190

SD = 1.144
N = 198

5th
N = 48

97.92%

Mean = 11.32

89.58%

Mean = 3.98

95.83%

Mean =

SD = 3.349

SD = 1.4704

2.543

N = 47

N = 44

SD = 1.5449
N = 46

Grad
Student
N = 167

92.81%

Mean = 11.28

85.63%

Mean = 3.61

88.62%

Mean = 2.30

SD = 3.29

SD = 1.46

SD = 1.24

N = 157

N=144

N = 148

Program of Study. Participants also were separated into their respective programs
of study, as determined by the demographic section of the questionnaire. One participant
did not specify their program of study and, therefore, this participant was not included in
this summary. Awareness levels and mean knowledge scores were calculated for each
cohort and for each section of the questionnaire (HPV, OPC, and HPV vaccine).
Awareness levels were calculated by determining the percentage of participants in each
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cohort who had previously heard of HPV, OPC, and the HPV Vaccine, respectively.
Mean knowledge scores for each section were generated using only the responses of
participants whom had either answered ‘yes’ to the corresponding awareness question or
left the awareness question blank, thereby granting them access to the knowledge
questions. Results are shown in Table 3 below.
Table 3. Awareness Levels and Mean Knowledge Scores by Program of Study

Program
of
Study

HPV
Awareness

Arts &
Humanities
N = 45

100%

Business
N = 82

Education
N=1
Engineering
N = 84

Health
Science
N = 364

IMS
N= 60

85.37%

HPV
Knowledge
(Possible
Range =
0-17)
Mean =

OPC
Awareness

68.89%

OPC
Knowledge
(Possible
Range = 06)
Mean =

Vaccine
Awareness

86.67%

Vaccine
Knowledge
(Possible
Range = 05)
Mean =

10.13

3.69

2.56

SD = 3.51

SD = 1.71

SD = 1.43

N = 45

N = 32

N = 39

Mean =

65.85%

Mean =

73.17%

Mean =

9.86

3.35

2.20

SD = 3.45

SD = 1.58

SD = 1.25

N = 71

N = 54

N = 60

100%

12 correct

100%

3 correct

100%

5 correct

88.10%

Mean =

67.85%

Mean =

87.80%

Mean =

96.15%

90.00%

9.80

3.39

2.28

SD = 3.66

SD = 1.41

SD = 1.36

N = 74

N = 59

N = 72

Mean =

89.84%

Mean =

94.23%

Mean =

11.29

4.04

2.43

SD = 3.20

SD = 1.39

SD = 1.18

N = 356

N = 328

N = 345

Mean =

66.67%

Mean =

93.33%

Mean =

54

Law
N = 37

97.30%

Music = 55

Schulich =
18

Science
N = 123

Social
Science
N = 135

90.90%

100%

90.24%

91.85%

10.17

8.57

2.13

SD = 3.23

SD = 1.53

SD = 1.19

N = 59

N = 42

N = 56

Mean =

67.57%

Mean =

86.11%

Mean =

10.72

3.44

2.32

SD = 3.49

SD = 1.39

SD = 1.35

N = 36

N = 25

N = 31

Mean =

70.90%

Mean =

85.45%

Mean =

8.13

2.95

1.85

SD = 3.54

SD = 1.50

SD = 0.97

N = 54

N = 42

N = 48

Mean =

77.79%

Mean =

88.89%

Mean =

12.00

4.43

3.13

SD = 3.29

SD = 1.34

SD = 1.44

N = 18

N = 14

N = 16

Mean =

72.36%

Mean =

81.30%

Mean =

9.72

3.65

2.23

SD = 3.20

SD = 1.54

SD = 1.28

N = 114

N = 90

N = 100

Mean =

75.56%

Mean =

87.41%

Mean =

10.30

3.53

2.203

SD = 3.46

SD = 1.48

SD = 1.14

N = 126

N = 104

N = 118

*1 participant did not indicate their program of study and was therefore excluded from
this summary.

Ethnicity. Due to the high number of Caucasian participants (73.6%), and the
relatively small number of participants in each of the other self-identified ethnicity
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cohorts, participants were grouped into one of two categories for this comparison:
Caucasian or Other. Awareness levels and mean knowledge scores were generated in the
same manner as the previous demographic variables and the results are presented below
in Table 4.
Table 4. Awareness Levels and Mean Knowledge Scores By Ethnicity

HPV
Awareness
Ethnicity
Caucasian
N = 740

All Other
Ethnicities
N = 265

94.73%

87.55%

HPV
Knowledge
(Possible
Range =
0-17)
Mean =

OPC
Awareness

81.08%

OPC
Knowledge
(Possible
Range = 06)
Mean =

Vaccine
Awareness

91.76%

Vaccine
Knowledge
(Possible
Range = 05)
Mean =

10.79

3.75

2.35

SD = 3.44

SD = 1.46

SD = 1.22

N = 716

N = 608

N = 682

Mean =

67.55%

Mean= 3.50

76.98%

Mean =

9.79

SD = 1.58

2.20

SD = 3.36

N = 183

SD = 1.26

N = 238

N = 204

Vaccination Status, Awareness and Knowledge. Participants were categorized into
three categories based on their HPV vaccination status: (1) not vaccinated, (2) vaccinated,
or (3) unsure. Participants were deemed vaccinated if they had received at least one dose
of the HPV vaccine (either Gardasil™ or Cervarix™). Five participants did not indicate
their vaccination status and were therefore excluded from this summary. Awareness
levels and mean knowledge scores were generated for each cohort and for each section of
the questionnaire and the collective results are shown in Table 5.
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Table 5. Awareness Levels and Mean Knowledge Scores by Vaccination Status

HPV
Awareness
Vaccine
Status
No Vaccine
N = 434

Vaccine
N = 412

Unsure
N = 154

92.17%

97.33%

83.12%

HPC
Knowledge
(Possible
Range =
0-17)
Mean =

OPC
Awareness

77.42%

OPC
Knowledge
(Possible
Range = 06)
Mean =

Vaccine
Awareness

85.71%

Vaccine
Knowledge
(Possible
Range = 05)
Mean =

10.81

3.69

2.3431

SD = 3.42

SD = 1.46

SD = 1.25

N = 406

N = 343

N = 373

Mean =

82.77%

Mean =

97.09%

Mean =

10.832

3.909

2.440

SD = 3.17

SD = 1.43

SD = 1.18

N = 411

N = 343

N = 402

Mean =

62.99%

Mean =

69.48%

Mean =

8.789

2.89

1.747

SD = 3.81

SD = 1.55

SD = 1.25

N = 133

N = 100

N = 107

*5 participants did not indicate their vaccine status and were therefore excluded.
Comparison of Mean Knowledge Scores Between Genders
As noted previously, an independent t-test was performed to test for potential
differences between males and females relative to mean knowledge scores of each of the
three knowledge sections and total knowledge scores. A Bonferroni correction was made
to the alpha level of p = .05 due to the fact four t-tests were performed. Therefore, an a
priori significance level of 0.0125 was used to test for significance.
HPV Knowledge. The effect of gender was not found to be statistically significant
in relation to HPV knowledge (t = 0.856, p = .393).
OPC Knowledge. The effect of gender was not found to be statistically significant
in relation to OPC knowledge (t = 0.214, p = .830).
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HPV Vaccine Knowledge. The effect of gender was not significantly different in
relation to HPV vaccine knowledge (t = 0.352, p = .725).
Total Knowledge Score. The difference between males’ and females’ total
knowledge scores was found to be statistically significant using a p value of 0.0125 (t =
4.009, p = .000).
Correlational Analyses of Knowledge Scores
Pearson product-moment correlation coefficients were generated to assess
potential relationships between HPV, OPV, HPV vaccine and total knowledge scores.
Male and females scores were correlated separately. Results for both males and females
indicated very strong correlations between HPV knowledge scores and total knowledge
scores. Strong correlations were also noted between OPC knowledge and total knowledge
and HPV vaccine knowledge and total knowledge. Weak-to-moderate correlations were
found between the three knowledge section scores (HPV to OPC, OPC to HPV vaccine,
and HPV to HPV vaccine). However, for males, a moderate correlation was noted
between HPV knowledge and HPV vaccine knowledge. Therefore, males who had higher
HPV knowledge scores also had higher HPV vaccine knowledge scores.
No correlation was found between age or year of academic study and knowledge
scores.
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Table 6 Correlational Analyses of Female Knowledge Scores

Age
Age

1

Year of
Study
HPV
Knowledge
OPC
Knowledge
Vaccine
Knowledge
Total
Knowledge
**
p<0.01 level (2-tailed)

Year of
Study
.836**
1

HPV
OPC
Vaccine
Total
Knowledge Knowledge Knowledge Knowledge
.156**
.169**
.070
.179**
.158**

.219**

.090*

.201**

1

.424**

.466**

.914**

1

.339**

.707**

1

.655**
1

Table 7 Correlational Analyses of Male Knowledge Scores

Age
Age

1

Year of
Study
HPV
Knowledge
OPC
Knowledge
Vaccine
Knowledge
Total
Knowledge
**
p<0.01 level (2-tailed)

Year of
Study
.818**
1

HPV
OPC
Vaccine
Total
Knowledge Knowledge Knowledge Knowledge
.043
-.045
.037
.024
.071

-.057

.059

.044

1

.444**

.556**

.937**

1

.372**

.685**

1

.710**
1
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CHAPTER 4
Discussion
The present study was designed to address three specific research objectives.
Those objectives were to:
1) Assess awareness and knowledge of HPV, HPV-related cancer, and the HPV
vaccine in a population of young adult university students;
2) Identify knowledge gaps in young adults' understanding of HPV, OPC, and the
HPV vaccine through a series of "true/false/I don't know" questions; and
3) Identify demographic variables that may lead to greater or lesser levels of
awareness and knowledge specific to the HPV-related topics identified above.

The discussion to follow will address the findings from the present study in relation to
the above stated objectives. In doing so, the discussion will first address relevant issues
specific to survey response rates and participant demographics (e.g., age, gender,
program of study, ethnicity). Next, the data gathered and its representation to each of the
three research objectives will be interpreted and discussed in relation to the current state
of literature. This will include an exploration of demographic variables that may lead to
greater or lesser awareness and knowledge of HPV, OPC, and the HPV vaccine. Finally,
limitations of the current research will be addressed, followed by the implications of the
present findings, directions for future research, and the overall conclusions that emerged
from this investigation.
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Response Rates
The overall response rate for this study was 19.3% (n = 1,005). Recruitment
Method 1 (approaching individuals directly) yielded a much higher response rate, as
69.8% (n=317) of the 454 people recruited using this method completed the survey.
Recruitment Method 2 (class announcements) yielded more responses overall (n=733),
despite a lower response rate of 14.7%. Overall, however, the present investigation
yielded a response rate that is consistent with previous research reported by
Ratanasiripong, Cheng, & Enriquez (2013) who utilized a web-based survey tool to asses
HPV knowledge levels of female college students in California.
Participant Demographics
Participants in this study included young adults between the ages of 18 and 30
who were currently registered students at The University of Western Ontario. This
population was chosen for the study because they represent the age cohort with the
highest prevalence of both cervical and oral cavity HPV infection (D’Souza et al., 2009;
Sellors et al., 2000; Steinau et al., 2014). Given the two methods of participant
recruitment, this sample can be considered one of fixed location convenience. However,
given the relatively large sample size of this study, this sample is believed to be
representative of the greater student population at Western University (see Appendix D
for Western University student demographics).
Gender. With respect to gender, 71% (n = 711) of the respondents to the present
survey were female and 29% (n = 292) were male. This proportion differed slightly from
the overall population of Western University, which is currently reported to be 55%
female and 45% male (see Appendix D). The high proportion of female participants in
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this study may be partially explained by the fact that a high proportion of respondents
(36.5%) were from the Faculty of Health Sciences and the Faculty of Social Sciences
(13.5%), which have higher proportions of females than males (71.5% and 55%,
respectively).
Given the significant difference that was identified for the total knowledge scores
between males and females in the present research, it is plausible that overall knowledge
levels may have decreased slightly had there been a higher proportion of male
participants in this study. This assumption is based on the fact that males had a
significantly lower total knowledge score than did females who participated in this study.
Had the number of male participants been equal to the number of female participants in
this study, the overall knowledge level of the present population also may have been
lowered. However, although this anticipated trend has been extrapolated from the present
sample, this assumption requires additional validation in future work.
Ethnicity. The self-identified ethnicity categories for which participants could
choose from were sourced from the 2006 Canadian Census (Statistics Canada, 2006).
While the researcher recognizes that no method of categorizing ethnicity is perfect,
especially in an ethnically diverse setting such as a university, the census categories were
chosen for this study because they represent the best means of categorizing one’s ethnic
identity, and consequently may provide the existing “gold standard” for this demographic
descriptor.
The majority of participants in this research (74%) self-identified as Caucasian.
“Caucasian” is a collective term used for people with lighter/“white” skin, but who may
not necessarily share similar ethnic backgrounds. The other ethnicity categories (e.g.,
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Chinese, Filipino, Korean, etc.) were much more specific, which may have led to fewer
respondents per category. No current data exist for the ethnic composition of Western
University; therefore, the sample obtained for this study cannot be compared to the
overall university population. However, given the large sample size obtained in this
study, it is reasonable to assume that the sample is representative of the greater Western
University population.
Faculty of Participant’s Enrollment. All of the 11 major faculties at Western
University were represented in this study’s participant sample. The Faculty of Health
Sciences accounted for the largest proportion of respondents, comprising 36.5% of the
total sample. Next, Social Science (13.5%) and Science (12%) faculties accounted for the
second and third highest proportion of respondents, respectively. Although each faculty
was not evenly represented in this sample, there is no reason to assume that members of
one faculty would have inherently better or worse HPV, OPC, HPV vaccine knowledge
or awareness than members of another faculty. This assumption is supported by the data,
which show only minor differences in awareness and knowledge levels between
respondents who came from different faculties.
HPV Vaccination Status. 40.9% of survey respondents indicated that they had
received at least one dose of the HPV vaccine. This overall vaccination rate comprised
51.6% of female respondents and 15.4% of male respondents. The 51.6% vaccination rate
for females in this sample is significantly lower when compared to the reported
vaccination rate of 70.2% for females in Ontario (Lim et al., 2013). However, Ontario’s
vaccination rates are based on statistics gathered from females in Grade 8, the age at
which the vaccine is initially available and/or provided in Ontario’s school-based
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vaccination program (Lim et al., 2013). The females who participated in the present
research would have been exposed to the HPV vaccination program at a time when the
vaccine was much newer and when coverage rates were much lower (e.g., 50% coverage
in 2007) (Lim et al., 2013). This finding suggests that as vaccination rates continue to rise
in elementary aged females, and these females subsequently become older, vaccination
coverage rates will naturally increase in university-aged individuals in the coming years.
The likely effect of this trend would then manifest as a decreased HPV infection
prevalence in this population. Obviously, efforts that seek to monitor such trends in the
years to come would be extremely valuable relative to understanding associated increases
in awareness and knowledge of HPV.
In contrast to females, data on male vaccination rates in Ontario are inconsistent
due to the fact there is no publically-funded HPV vaccination program for males in
Ontario. However, data from a national sample of males aged 13-17 in the United States
estimates an HPV vaccination rate of 34.6% (Center for Disease Control and Prevention,
2014), a rate that is more than doubled from the 15.4% vaccination rate of males who
participated in the current sample.
Interestingly, fully 30% of male respondents in this study were unsure of their
vaccination status. This surprising finding is likely tied to the fact that close to 24% of
male respondents in this study had never heard of the HPV vaccine prior to this study.
One possible explanation for this finding may be that vaccination efforts have primarily
been targeted at females in Ontario. As such, health promotion and health education
materials (advertising, public service announcements, etc.) and health care provider
recommendations have mostly excluded males. This finding also may speak to a certain
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level of unawareness in males relative to HPV, a topic that will be discussed further in
the sections to follow.
Year of University Study. The distribution of participants based on their year of
university study was relatively even compared to the University population as a whole.
The one exception to this finding is the relatively smaller proportion of students in their
first year of study compared to students in other, later years of study. This discrepancy in
part may have resulted from a sampling bias or a simple non-response bias. As some
students in their first year of study are potentially under the age of 18, some may have
been prevented from participating in this study due to age being one of the exclusion
criteria. However, it is unclear how many potential participants this may have affected. It
also is possible that younger students may have been less interested in participation in
academic research or deemed the study unimportant. In the latter case, if a determination
that the study was unimportant drove the decision not to participate for those in their first
year, substantial concerns clearly arise. More specifically, sexual activity by university
students is not uncommon (Chandra et al., 2011), therefore, not realizing the potential
risks associated with such activity (e.g., HPV infection) poses a considerable challenge
for this population. This would certainly raise questions about the ideal time for
education concerning HPV and the associated risks. It also suggests that increasing age
that corresponds to year of university study also carries with it some relative advantage.
In general, knowledge and awareness seemed to improve with increasing year of
study. When participants were separated by their year of study, the lowest awareness
levels and lowest mean knowledge scores were found for those participants who were in
either their first or second year of study. This was true across all three knowledge
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categories (HPV, OPC, and HPV vaccine). This finding suggests that level of education
may play some role in one’s increasing knowledge and awareness of HPV, OPC, and
HPV vaccine. Previous research in a sample of the general population has confirmed that
education level is significantly associated with awareness of HPV (Marlow et al., 2013).
Findings Specific to Research Objectives
HPV Awareness. A very high rate (92.94%) of participants had heard of HPV
prior to their participation in this study. The high level of HPV awareness in this sample
is in line with previous research that has assessed awareness of HPV in a sample of
university students. These previous studies have reported awareness rates of between
94% and 96%, although they have primarily focused only on females (Dillard & Spear,
2011; Krawczyk et al., 2012). The higher awareness levels in females (95.07%) versus
males (87.33%) found in the present study is also consistent with the results of previous
research which compared awareness levels of males and females (Dahlström et al., 2012;
Marlow et al., 2013; Reimer, Schommer, Houlihan, & Gerrard, 2014). Again, exposure to
information on HPV and its vaccine, as well as associated advertising and educational
materials for females is likely an influencing factor for this finding. Perhaps if males had
more exposure to information or greater opportunities to receive the vaccine, males’ HPV
awareness would begin to approximate the awareness levels observed in our female
participants.
Caucasian participants had higher levels of HPV awareness (94.73%) than did
non-Caucasian participants (87.55%). This finding is consistent with previous research,
as Reimer et al. (2014) have previously linked Caucasian ethnicity as a significant
predictor of higher HPV Awareness levels. While more aware of HPV, a national sample

66
of adults in the United States revealed that Caucasian individuals also engage in oral sex
practices more often than people of other races (Chandra et al., 2011). Interestingly,
having a higher level of education also was related to having two or more vaginal sexual
partners within the last year for males and more frequent oral sex for both men and
women (Chandra et al., 2011).
HPV Knowledge. Although a relatively high level of general awareness was
present in the present participant sample, HPV knowledge varied greatly by individual
knowledge item. As outlined in the methods, HPV knowledge was assessed through a
series of 17 “true/false/I don’t know” questions. In total, 954 participants completed the
HPV knowledge section of the survey. The mean summed knowledge score of these 954
participants was 10.54 out of a potential high score of 17 (range = 0-17), reflecting a
moderate level of HPV knowledge.
Certain general facts about HPV were fairly well known, suggesting that young
adults in the current sample have been exposed to a least some form of HPV education,
whether or not that exposure has been provided in a formal manner. This theory is further
supported by the fact that 60.5% of respondents to this survey reported that they had
received some information or knowledge of HPV from school. This previous exposure
may explain the fact of why respondents were able to correctly answer certain HPV
knowledge questions. For example, 85.2% of respondents to the HPV knowledge section
correctly identified HPV as a sexually transmitted infection, while 91.4% of respondents
knew that using an oral contraceptive does not protect against HPV infection, and finally,
85.8% of respondents knew that HPV infections could be asymptomatic for many years.
Furthermore, 80.4% of all respondents to this section knew that men could become
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infected with HPV. Similar findings have been observed by Krawczyk et al. (2012)
relative to university students’ knowledge that HPV is a sexually transmitted infection.
The present findings, in addition to those of Krawczyk et al. (2012), represent examples
of positive results of past sexual education programs. As mentioned previously,
knowledge is an important first step in the prevention of HPV, as well as other types of
sexually transmitted infections. It is, therefore, encouraging to find that a high proportion
of the university students who participated herein are at least able to identify the sexually
transmitted nature of HPV. Given that sexual experimentation is a common endeavor for
many university students, building on this rudimentary knowledge of HPV will be an
important goal for future educators.
Certain risk factors for HPV were also fairly well known by respondents of the
present study. For example, 86.2% of respondents correctly identified that having a high
number of lifetime sexual partners is an important risk factor for HPV and 75.4%
correctly noted that condoms do not completely protect against HPV infection during
intercourse of any kind. Less well known was the fact that HPV can be spread through
oral and anal sex, with 63.8% and 68.4% of respondents, respectively, correctly
identifying these behaviours as substantial risk factors. The fact that roughly one-third of
respondents to this survey did not know that oral or anal sex may lead HPV infection
should be of concern and may be leading to unsafe sexual practices. This conclusion is
based on a national sample from the Unites States which found that approximately 89%
of women and 90% of men aged 15-44 have performed oral sex. Furthermore, 36% of
women and 44% of men have reported engaging in anal sex with an opposite-sex partner
(Chandra et al., 2011).
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The collective results outlined above indicate that the young adults in this sample
may posses at least a basic understanding of HPV and the associated risk factors for
acquiring an HPV infection. However, in contrast, the potential consequences of HPV
infection were not as well known. Only 57.1% of respondents in the present study knew
that HPV can cause genital warts. Compared to a similar survey by Ratanasiripong et al.
(2013) which assessed HPV knowledge in a sample of female college students in
California, these results are quite similar. In that study, 43.5%-46.9% of their participants
knew HPV could cause genital warts. These data suggest that knowledge levels of the
present sample are slightly higher relative to these two knowledge items, but overall,
young adults continue to require more education relative to the potential consequences of
HPV infection.
Perhaps the biggest knowledge gaps that were identified from the HPV
knowledge portion of the current study were those related to HPV’s association with
certain cancers. For example, 64.6% of respondents who completed the knowledge
section of the present survey correctly identified HPV infection as the main cause of
cervical cancer. This finding was surprising due to the fact that HPV is essentially the
sole cause of this type cancer. Since the release of the HPV vaccine and subsequent
public health vaccination programs in 2007, opportunities for HPV education have
undoubtedly increased. This is in addition to regular cervical cancer screening programs
that are common in most economically and socially developed countries. Despite this
increased attention and energy that is directed toward preventing cervical cancer in
women, fewer than 65% of the respondents to this survey correctly identified the link
between HPV and cervical cancer.
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Comparatively, 41.8% of respondents identified HPV infection as a risk factor for
oropharyngeal cancer and only 26.7% of participants identified HPV infection as a risk
factor for anal cancer. One possible explanation for these findings may be the relatively
low incidence of these two types of cancer in North America when compared to other
forms of malignancy. Anecdotally, it is true that more prevalent cancers, such as breast,
lung, colon, and prostate, dominate North American popular culture and public interest.
Interestingly, however, is the fact that many of the respondents to the present survey
indicated that they first learned of the link between HPV and OPC from actor Michael
Douglas, who was diagnosed with HPV-positive OPC in 2010.
Based on the data obtained in the current investigation, participants were largely
unaware of the association between HPV and cancer, especially its relationship to
oropharyngeal and anal cancer. Knowledge of HPV’s relation to cervical cancer was
again similar to findings from previous samples of Canadian university students in which
61% of respondents were aware of the association (Krawczyk et al., 2012). However,
other studies have shown much higher levels of knowledge in relation to the link between
HPV and cervical cancer. For example, a study by Ratanasiripong et al. (2013) found that
86.3% of female Californian college students respondents were aware of the link between
HPV and cervical cancer. The present research did find that a higher proportion of
females (69.4%) than males (52.1%) knew about the relation of HPV to cervical cancer.
However, the female participants in the study by Ratanasiripong et al. (2013) still
demonstrated higher knowledge levels relative to this fact than did the females who
participated in the present research.
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In contrast to the above noted comparisons, fewer studies have addressed whether
people understand the association between HPV and oral/oropharyngeal cancer. This
observation exists despite a 225% increase in incidence of HPV-positive OPC between
1988 to 2004 in the United States (Chaturvedi et al., 2011). A national sample of men in
the United States revealed that only approximately one-in-five (21%) men were aware of
the association between HPV and OPC (Reiter et al., 2010). The present sample revealed
nearly double the level of knowledge relative to this fact which is comparable to the
findings of a study from Italy (Pelullo et al., 2012) in which 31%-47% of participants,
who were identified as either lesbian, gay, or bisexual, were aware of the association.
Similar to the above findings, fewer than 27% of respondents of the present study
knew that HPV was a risk factor for anal cancer. This was by far the least understood
association between HPV and cancer. This poor knowledge of HPV as a risk factor for
anal cancer also was found in the study by Reiter et al. (2010); only 14% of men were
aware of this association. Although homosexual men are at an increased risk for anal
cancer (Machalek et al., 2012), this should be a concern for heterosexual men and their
female partners as well. As mentioned previously, approximately 44% of men in the
United States report having had anal sex with a female partner (Chandra et al., 2011).
Together, these findings confirm that while most people have heard of HPV,
significant gaps in HPV-related knowledge still exist. Thus, while awareness is a
necessary and crucial component of one’s understanding of HPV, it does not offer the
whole picture. In other words, having a complete understanding of the virus relative to
risks and potential consequences is much more likely to influence behaviour than simply
knowing that the virus exists. Ongoing educational efforts must address the knowledge
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gaps identified in this population - most notably, knowledge of the associations between
HPV and cancers of the cervix, oropharynx, and anus. Efforts to educate the population
about these HPV-related cancers will be imperative as the incidence of both
oropharyngeal and anal cancers continue to rise (Chaturvedi et al., 2011; Jemal et al.,
2013)
Oropharyngeal Cancer Awareness. HPV-positive OPC incidence has been rising
drastically in developed countries such as Canada and the United States in recent decades
(Chaturvedi et al., 2011; Nichols et al., 2013). This trend has prompted organizations
such as the United States Centers for Disease Control and Prevention and The World
Health Organization to label this trend as an epidemic. Relative to other cancers, HPVrelated OPC was a relatively unknown disease up until quite recently. Previous studies
have not explicitly investigated public awareness or knowledge of this cancer. However,
as incidence rates of HPV-related OPC continue to increase, gaining an understanding of
awareness levels and knowledge gaps may be highly valuable for future educational
development. Therefore, in an effort to further investigate what young adults know about
this particular type of HPV-related cancer, this study explored awareness and knowledge
relative to oropharyngeal cancer and its risk factors.
The results of this study found that 77.5% of participants (n=779) had heard of
OPC prior to this survey. As a single independent measure, a 77.5% awareness rate in
this population could be considered good. Unfortunately, no similar studies or data could
be found to compare this finding. As with HPV awareness and knowledge, relatively high
awareness levels may not directly translate to high levels of knowledge. Therefore, OPC
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knowledge was assessed further in this population in an effort to identify its potential
link(s) to awareness.
Oropharyngeal Cancer Knowledge. OPC knowledge was assessed through a
series of six “true/false/I don’t know” questions. Overall, 791 of the 1005 participants
completed the OPC knowledge section of the survey. Of these 791 respondents, over
90% correctly identified smoking tobacco as a risk factor for OPC and additionally that
both men and women are susceptible to OPC. However, the remaining four questions of
the OPC knowledge section were answered much less accurately. For example, less than
half (48.2%) of the present respondents on this section knew that the incidence of OPC is
currently rising in Canada. Furthermore, only 39.7% of respondents correctly identified
consuming alcohol as a risk factor for OPC.
With respect to OPC and its relation to HPV, 51% of respondents to this section
knew that HPV infection was a risk factor for OPC. Similarly, only 48% knew that
having a higher number of lifetime oral sexual partners increased the chances of
acquiring OPC. There were no differences between male and females with respect to
these two questions. Previous studies that have assessed knowledge of oral/oropharyngeal
cancer have typically focused on populations of dental or other health professionals and,
therefore, no appropriate data are available for comparison to this study’s sample
(Applebaum, 2009; Cannick, Horowitz, Drury, Reed, & Day, 2005). However, the
relatively low level of knowledge relative to OPC and HPV may speak to a general lack
of understanding about this type of cancer in the population studied. This conclusion is
further supported by the fact that the overwhelming majority (i.e., 86.3%) of participants
in this study rated their self-perceived level of knowledge regarding OPC as either
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“nothing” or “a little bit”. This finding suggests that young adults may be engaging in
clearly risky sexual behaviours without the understanding that their behaviour is in fact
risky. Further efforts to educate individuals about the simple risk factors related to OPC
may be warranted, and should be encouraged, as the incidence of this cancer continues to
increase in the coming decades.
HPV Vaccine Awareness. 833 (87.86%) of the 1,005 participants in this study had
previously heard of the HPV vaccine (either Gardasil™ or Cervarix™). HPV vaccine
awareness was much higher in females (93%) compared to males (75.7%) and this result
was expected due to the fact the vaccine has been primarily marketed towards - and
provided free of cost - to females only in Ontario since its introduction in 2007. Female
HPV vaccine awareness levels were consistent with findings from similar samples of
female university students in both Canada and the United States, who had a 91% and
95% vaccine awareness rate, respectively (Krawczyk et al., 2012; Ratanasiripong et al.,
2013). Male vaccine awareness in this study was slightly higher than the vaccine
awareness level of 63% found by Reiter et al. (2010) in a national sample of American
men. The difference in awareness levels between these two studies may be explained by
the fact that the HPV vaccine had not yet been approved for use in males at the time
when Reiter et al. (2010) collected their data.
Now that the HPV vaccine has been approved for use in males (Centers for
Disease Control and Prevention, 2011), and is being routinely administered to males in
provinces such as Alberta and Prince Edward Island, further education efforts should
focus on increasing awareness and knowledge of the HPV vaccine in males. The
possibility of increasing vaccination rates in males presents a significant opportunity to
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increase vaccination coverage among the entire population and subsequently, may
drastically reduce the prevalence of HPV infection and its resulting morbidities. This may
be especially important for men who have sex with men, as these individuals are at an
even higher risk for HPV infection and are not protected under female-only vaccination
programs. Therefore, increasing both awareness and knowledge levels specific to HPV
and the HPV vaccine should be a high priority for educators and health care providers
moving forward. This conclusion is supported by a systematic review by Nadarzynski,
Smith, Richardson, Jones, & Llewellyn, (2014) which found that MSM who were aware
of HPV expressed greater willingness to receive the vaccine.
HPV Vaccine Knowledge. HPV vaccine knowledge was assessed through a series
of five “true/false/I don’t know” questions. 886 of the 1,005 participants in this study
completed the HPV vaccine knowledge section. The relatively high levels of vaccine
awareness did not translate to high levels of vaccine knowledge. In fact, vaccine
knowledge was quite poor relative to the other knowledge sections of this survey. For
example, less than half of respondents (47.7%) knew that men could receive the HPV
vaccine. Previous studies have found much greater knowledge relative to this fact. A
study of Canadian adult females in Ontario found that 71% of respondents knew that men
could receive the HPV vaccine (Sadry, Souza, & Yudin, 2013). Again, increasing the
knowledge of this fact and the access to vaccination, especially in males, may provide an
opportunity for increased vaccine uptake.
Perhaps the most surprising finding from this research was the observation that
only just more than half of respondents (51.5%) to the vaccine knowledge section knew
that the vaccine protects against cervical cancer. Furthermore, only 27.3% of the
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respondents to this section knew that the vaccine protects against genital warts. These
findings were surprising for two reasons: First, both of the HPV vaccines currently in use
(Gardasil™ and Cervarix™) were explicitly developed in order to prevent cervical cancer
in females. Gardasil™, the more popular of the two vaccines in Ontario, also protects
against genital warts. Second, 40.9% of the participants in this study reported having
received at least one dose of the HPV vaccine, meaning that at least some participants
received the vaccine without knowing why it was administered. These findings suggest a
clear distinction between awareness and knowledge about the HPV vaccine. While 87.7%
of respondents had previously heard of the vaccine, only 51.5% of these individuals knew
the vaccine’s main purpose. This lack of knowledge regarding the HPV vaccine may be
related to the generally poor knowledge of the consequences of HPV infection. In other
words, there may be confusion about the purpose of the HPV vaccine for individuals who
do not know the association between HPV and cervical cancer/genital warts. Yet, it is
also conceivable that the consequences are known, but that they are disregarded in the
context of the commonality of sexual practices in this age group.
One question in this section was, however, answered correctly by a large
proportion of respondents; 88.8% of participants correctly noted that once vaccinated,
women must still receive regular cervical cancer screening. A similarly high proportion
of respondents answered this question correctly in a study by Ragin et al. (2009).
Influence of Demographic Variables
Age. Based on the correlations generated, no relationships between age and
awareness or knowledge were identified in the present study.
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Year of University Study. Overall, a clear pattern was noted between year of
university study and both awareness and knowledge levels or HPV, OPC, and the HPV
vaccine. However, correlational analyses revealed weak correlations between year of
University Study and knowledge scores.
Program of Study. Comparisons of awareness and knowledge levels between
respondents in different programs of study were somewhat difficult to perform given the
unequal representation of each faculty in the sample. However, no noteworthy
differences were noted in awareness or knowledge of HPV between the programs of
study. With respect to HPV vaccine awareness, respondents from the Faculty of Health
Sciences and the Faculty of Information & Media Studies had the highest levels (94%
and 93%, respectively. This may be due to the fact that the majority of respondents from
these faculties were female (84% and 90%, respectively). Participants enrolled in
Schulich School of Medicine and Dentistry demonstrated noticeably higher levels of
HPV vaccine knowledge, suggesting individuals in this faculty have had a greater
exposure to this information within their prior or current education given their potential
future plans to work within a medically related area.
Ethnicity. Compared to non-Caucasian respondents, Caucasian individuals
demonstrated much higher levels of both awareness and knowledge for all categories.
This finding is consistent with previous research by both Sadry et al. (2013) and Joseph et
al. (2014) which found significantly higher HPV awareness and knowledge in Caucasian
compared to non-Caucasian adult females.
Vaccination Status. Somewhat surprisingly, there were very minimal differences
between awareness and knowledge of HPV and the HPV vaccine between people who
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have been vaccinated and those who have not. However, individuals who were unsure of
their vaccination status had much lower levels of awareness and knowledge.
Gender. As mentioned previously, females had higher levels of both awareness
and knowledge for all three categories. Statistical analyses of the data revealed no
statistically significant differences in any of the knowledge sub-scores, however, a
statistically significant difference between male and female total knowledge scores was
identified. These findings were expected given results of previous studies which have
shown major differences in knowledge levels of HPV between males and females
(Dahlström et al., 2012; Gerend & Magloire, 2008; Gollust et al., 2013).
Implications of the Present Findings
As discussed previously, HPV infection is extremely prevalent in young adults
aged 18-30. While the majority of these infections are believed to clear spontaneously
with no residual effects, a number of HPV-related infections and subsequent
consequences have become increasingly prevalent in recent decades. Furthermore, other
HPV-related morbidities such as genital warts also are most prevalent in this age group
(Koutsky et al., 1998). Therefore, having an accurate estimate of what this young adult
population (age 18-30) knows about HPV, HPV-related cancers, and the HPV vaccine
has important implications for educators, policy makers, and health care providers tasked
with preventing HPV-related morbidity and mortality.
The findings of the present study have clearly identified both strengths and
weaknesses in young adults’ understanding of HPV, HPV-related cancers, and the HPV
vaccine. More directly, clear knowledge gaps exist in both general awareness related to
HPV, as well as more comprehensive knowledge related to its potential health
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consequences. Based on the present data, efforts that enable future education programs
to build on existing knowledge, while simultaneously seeking to address common
misconceptions or unknowns may be enhanced.
Since knowledge is a necessary precursor for health-protective behaviours,
including the decision to become vaccinated, addressing these knowledge gaps may
enable young adults to make better choices. For example, increasing knowledge of HPVrelated morbidities may lead to safer sexual practices among university students.
Similarly, increasing vaccine knowledge, especially in males, could lead to higher
vaccine coverage rates and decreased HPV prevalence. Furthermore, doing so may
provide direct and observable health benefits.
Over 60% of the participants in the current study identified “school” as a source
of their HPV information. This finding suggests that the best place to address some of the
knowledge gaps identified herein is within the educational “school” setting. The province
of Ontario has recently reformed their sexual education curriculum, including discussions
of sexually transmitted infections and safe sex practices. Because of this reform, it will be
interesting to see how knowledge may be influenced by this change in the years to come.
Health care providers also will have an important role to play in further education
regarding HPV and the HPV vaccine. In this regard, 31.4% of participants in this study
reported a “health care provider” as a personal source of HPV information. Furthermore,
previous studies have shown that a health care provider’s recommendation is an
extremely important factor in many people’s decision to receive the HPV vaccine
(McRee, Katz, Paskett, & Reiter, 2014; Perkins et al., 2013).
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Limitations of the Present Study
As with any research project, limitations of the present study must be
acknowledged and considered. First, the sample obtained in this study contained a
disproportionately high proportion of females compared to the general population of
Western University. This was likely a result of a sampling bias or response bias that
favoured students enrolled in the Faculty of Health Sciences where a greater number of
females are enrolled. However, given the minimal differences in awareness and
knowledge levels observed between individuals from different faculties, the overrepresentation of Health Sciences students in this sample likely did not change the
findings in any meaningful way. Furthermore, while Health Sciences students may be
considered more “health-conscious” in general, there is no reason to assume they have
better or poorer understanding of HPV, OPC, or the HPV vaccine – or that their
experiences with these subjects are any different when compared to other students.
Given that a significant difference in total knowledge scores was found in this
study between males and females, the high proportion of female students in this sample
relative to the population as a whole may have contributed to some sampling bias, and
thus, some skewing of the data. If this did, in fact, effect the data in any way, it would
likely result in an overestimation of actual awareness and knowledge levels in this
population given that females were found to have higher levels of both compared to
males. Two factors are relevant to this limitation; first, the findings of this study were
generally in line with previous studies that have assessed knowledge and awareness in
samples of university students; and second, the large sample size of 1,005 acquired in this
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study may increase confidence that that data obtained are representative of a larger
population sample.
An additional limitation of this study is the survey tool utilized for data collection.
This measurement tool was designed specifically for this study and the items of the
survey were adapted from tools used in previous studies, some of which were validated.
While the tool that was developed did undergo a face validity assessment by 10 current
university students, the measure itself was not validated. Therefore, issues of reliability
and validity need to be considered when interpreting the results of this study.
Finally, the population studied in this research is not representative of the entire
population at large. The population of 18-30 year old university students was chosen for
this research due to the very high prevalence of HPV infection and potentially risky
sexual behaviour in this population. While the sample obtained is believed to be
representative of the population in question, the findings of this research cannot be
generalized to the population at large (i.e., individuals younger than 18 or over 30 years
old).
Thus, despite the considerably large sample obtained herein, the external validity
of these data must be considered carefully. Given the increased levels of awareness and
knowledge found with increased education level in this study, in addition to previous
studies that have reported much lower levels of awareness and knowledge in the
population at large (Donahue et al., 2014; Nielsen et al., 2009), awareness and knowledge
levels found at present are likely higher than those of the general population.
Nevertheless, despite the limitations noted above, this study does provide valuable
insights into the current levels of awareness and knowledge relative to HPV, OPC, and
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the HPV vaccine in a large sample of university students. The students in this sample
demonstrated good awareness of the topics in question; further, some basic knowledge of
HPV, OPC and the HPV vaccine was revealed. However, this study has clearly identified
specific knowledge gaps and opportunities for future education. Based on these insights,
some directions for future research will be discussed in the subsequent section.
Directions for Future Research
While awareness and knowledge are important considerations when determining
what factors lead people to adopt health-protective behaviours, they only comprise two
pieces of a larger puzzle. For example, further research might address how demographic
factors such as ethnicity or gender may influence behaviour, including the decision to
receive the HPV vaccine. Further research is also needed to determine the psychosocial
and contextual factors that influence awareness and knowledge of HPV, OPC, and the
HPV vaccine. This work should include an attempt to identify barriers and facilitators
(both real and perceived) of safe sexual behaviours and vaccination decisions. This may
be of particular importance to those who are sexually active, including university aged
young adults. Future work also may benefit from building on work by Fisher (2012),
Ratanasiripong et al. (2013), and others who have utilized health behaviour theories to
understand HPV vaccination uptake, or the lack thereof, in young adults.
Finally, strategies to address expanded educational programs and knowledge gaps
identified by this research will need to be developed. Questions such as when to provide
education, to whom, and in what setting will need to be addressed. Most importantly,
opportunities to translate this education into behavioural action will need to be
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implemented. Nevertheless, this issue of “how” educational opportunities can be
translated into behavioural actions will also need to be determined.
Summary and Conclusions
This research investigated young adults’ awareness and knowledge of HPV, OPC,
and the HPV vaccine. Based on the data gathered from this research study, several
conclusions may be made. First, clear and significant gaps in knowledge of HPV, OPC
and the HPV vaccine exist in this population. More explicitly, this research showed poor
understanding of the potential consequences of HPV infection. Most notably, the young
adults in this sample were largely unaware of the association between HPV and cancers
of the anus and oropharynx. This knowledge gap will need to be addressed, especially if
the incidence of these two types of cancers continues to increase steadily, as has been
observed and documented in recent decades.
Second, males in particular seem to have less awareness and knowledge relative
to the topics addressed in this study. This may be a result of previous HPV and HPV
vaccine information that has been primarily directed towards females. Ongoing efforts to
increase awareness and knowledge in the entire population should pay particular attention
to males, given that HPV-related cancers are increasingly prevalent in males.
Finally, this study did find that most individuals had awareness and at least a
basic understanding of HPV. The knowledge strengths identified by this study may
provide a starting point for future educational efforts. Educational efforts that increase
awareness and knowledge of HPV, HPV-related morbidities, and the HPV vaccine may
ultimately lead to direct health benefits in the population at large.
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APPENDIX C
Study Questionnaire
Demographics
1) What is your age in years and the closest number of additional months (e.g.,
20 years, 7 months)? ______ Yrs, ______Mths
2) What gender do you identify with?

Male

Female

Other

3) What race/ethnicity do you identify with?














Caucasian (white)
Chinese
South Asian (East Indian, Pakistani, Sri Lankan, etc.)
Black
Filipino
Aboriginal
Latin American
Southeast Asian (Vietnamese, Cambodian, Malaysian, Laotian, etc.)
Arab
West Asian
Korean
Japanese
Other (please specify) _____________________________

4) Please identify your current level of education








1st year undergrad student
2nd year undergrad student
3rd year undergrad student
4th year undergrad student
5th year undergrad student
Graduate Student
Other (please specify) ________________________

5) In which faculty are you enrolled?







Arts and Humanities
Business
Dentistry
Education
Engineering
Health Sciences
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Information and Media Studies
Law
Schulich School of Medicine and Dentistry
Music
Science
Social Science

6) Have you received one or more doses of the Human Papillomavirus (HPV)
vaccination?





Yes, one dose
Yes, two doses
Yes, three doses
No

7) Where did you obtain your knowledge of HPV?








Family members
School
Friends
A doctor or nurse
The internet
The media (television, radio, movies, etc.)
Other (please specify) ________________________

HPV Awareness
8) Prior to this survey, have you ever heard of the Human Papillomavirus
(HPV)?2
Yes
No
General Question on HPV
9) On a scale of 1-5 (with 1 being ‘not concerned at all’ and 5 being ‘extremely
concerned’, how concerned are you about becoming infected with HPV?4
Not concerned
at all
1

2

3

4

Extremely
concerned
5

10) On a scale of 1-5 (with 1 being ‘nothing’ and 5 being ‘very much/expert’),
how much would you say you know about HPV?
Nothing
1

2

A moderate amount
3
4

Very much/Expert
5

100
HPV Knowledge
11) HPV is a sexually transmitted infection1,3 (T)

True False I don’t know

12) HPV infection is rare in Canada3 (F)

True False I don’t know

13) A person could have HPV for many years without knowing it3 (T)
True False I don’t know
14) Men cannot get HPV1,3 (F)

True False I don’t know

15) There are many different types of HPV3 (T)

True False I don’t know

16) HPV is the main cause of cervical cancer1,2,3 (T)

True False I don’t know

17) HPV infection can cause oropharyngeal (mouth and throat) cancer2 (T)
True False I don’t know
18) HPV infection can cause genital warts1,3 (T)

True False I don’t know

19) HPV infection can cause HIV/AIDS3 (F)

True False I don’t know

20) HPV usually does not need any treatment3 (T)

True False I don’t know

21) HPV infection can cause anal cancer2 (T)

True False I don’t know

HPV Risk Factors
22) Having a higher number of sexual partners increases the risk of contracting
HPV2.3 (T)
True False I don’t know
23) One can become infected with HPV by having unprotected oral sex1,2 (T)
True False I don’t know
24) Using condoms during intercourse completely protects one from becoming
infected with HPV1,2,3 (F)
True False I don’t know
25) One can become infected with HPV by having unprotected anal sex1,2 (T)
True False I don’t know
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26) Having sex at an earlier age increases the risk get getting HPV3 (T)
True False I don’t know
27) Using an oral contraceptive (the birth control pill) protects me from
becoming infected with HPV2 (F)
True False I don’t know
Oropharyngeal Cancer Awareness
28) Prior to this survey, have you ever heard of oropharyngeal cancers (cancer
of the throat, base of tongue, soft palate, and/or the tonsils)?2
YES

NO

General oropharyngeal cancer questions
29) On a scale of 1-5 (with 1 being ‘not concerned at all’ and 5 being ‘extremely
concerned’), how concerned are you about getting oropharyngeal cancer?4
Not concerned
at all
1

2

3

4

Extremely
concerned
5

30) On a scale of 1-5 (with 1 being ‘nothing’ and 5 being ‘very much/expert’),
how much would you say you know about oropharyngeal cancer?
Nothing
1

2

A moderate amount
3
4

Very much/Expert
5

Oropharyngeal Cancer Knowledge
31) Both men and women can get oropharyngeal cancer5 (T)
True False I don’t know
32) The number of new cases of oropharyngeal cancer in Canada is increasing6
(T)
True False I don’t know
33)Smoking tobacco increases the risk for getting oropharyngeal cancer5 (T)
True False I don’t know
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34)Having a high number of lifetime oral sex partners increases the risk for
getting oropharyngeal cancer5 (T)
True False I don’t know
35) Drinking alcohol increases the risk of getting oropharyngeal cancer5 (T)
True False I don’t know
36) Having an HPV infection increases the risk of getting oropharyngeal cancer2,5
(T)
True False I don’t know
HPV Vaccine Awareness
37) Prior to this survey, have you ever heard of the HPV vaccine (brand names
Gardasil© or Cervarix©)2
YES NO
HPV Vaccine Knowledge
38) Men cannot obtain the HPV vaccine7 (F)

True False I don’t know

39) The HPV vaccine protects against cervical cancer2,7 (T)
True False I don’t know
40) The HPV vaccine protects against genital warts7 (T)
True False I don’t know
41) The HPV vaccine protects against oropharyngeal cancer2 (T)
True False I don’t know
42) Once vaccinated, women no longer have to receive regular cervical cancer
screening (pap smears)7 (F)
True False I don’t know
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The items of this questionnaire were based on information from, or adopted directly
from, the following publications:
1

Questions from Ramirez, J. E., Ramos, D. M., Clayton, L., Kanowitz, S., Moscicki, a B.
(1997). Genital human papillomavirus infections: knowledge, perception of
risk, and actual risk in a nonclinic population of young women. Journal of
Women’s Health, 6(1), 113–21.

2

Questions adapted from Pelullo, C. P., Di Giuseppe, G., & Angelillo, I. F. (2012).
Human papillomavirus infection: knowledge, attitudes, and behaviors among
lesbian, gay men, and bisexual in Italy. PloS One, 7(8), e42856.

3

Questions adapted from Bowyer, H. L., Marlow, L. a V, Hibbitts, S., Pollock, K. G., &
Waller, J. (2013). Knowledge and awareness of HPV and the HPV vaccine among
young women in the first routinely vaccinated cohort in England. Vaccine,
31(7), 1051–6. doi:10.1016/j.vaccine.2012.12.038

4

Question adapted from Gerend, M. a, & Magloire, Z. F. (2008). Awareness,
knowledge, and beliefs about human papillomavirus in a racially diverse
sample of young adults. The Journal of Adolescent Health, 42(3), 237–42.

5

Questions were developed based on OPC risk factors identified by Gillison, M. L.,
D’Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008).
Distinct risk factor profiles for human papillomavirus type 16-positive and
human papillomavirus type 16-negative head and neck cancers. Journal of the
National Cancer Institute, 100(6), 407–20.

6

Question was developed based on data from Nichols, A. C., Palma, D. A., Dhaliwal, S.
S., Tan, S., Theuer, J., Chow, W., … Barrett, J. W. (2013). The epidemic of human
papillomavirus and oropharyngeal cancer in a Canadian population. Current
Oncology (Toronto, Ont.), 20(4), 212–9.

7

Questions adapted from Ragin, C. C., Edwards, R. P., Jones, J., Thurman, N. E., Hagan,
K. L., Jones, E. a, … Taioli, E. (2009). Knowledge about human papillomavirus
and the HPV vaccine--a survey of the general population. Infectious Agents and
Cancer, 4 (1), S10.
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